var title_f21_56_22400="LVRS survival curves";
var content_f21_56_22400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    LVRS survival curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 453px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of the cumulative probability of death as a function of years after randomization to lung volume reduction surgery (LVRS, red line) or medical treatment (blue line) for (A) all patients in the National Emphysema Treatment Trial and (B - D) non-high-risk and upper-lobe-predominant emphysema subgroups of patients. The p value is from the Fisher exact test for difference in the proportions of patients who died during the 4.3 years (median) of follow-up. A) All patients (N - 1218). B) Nonhigh-risk patients (n - 1078). C) Upper-lobe-predominant and low baseline exercise capacity (n - 290). D) Upper-lobe-predominant and high exercise capacity (n - 419).",
"    <div class=\"footnotes\">",
"     RR: relative risk.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Naunheim, KS, Wood, DE, Mohsenifar, Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82:431. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22400=[""].join("\n");
var outline_f21_56_22400=null;
var title_f21_56_22401="Intraarticular fracture of the great toe proximal phalanx";
var content_f21_56_22401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraarticular fracture of the great toe: AP and oblique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On the image to the right, the oblique fracture line can be seen extending into the inter-phalangeal joint. The triangular-shaped fracture fragment contains 80 to 90 percent of the articular surface of the joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22401=[""].join("\n");
var outline_f21_56_22401=null;
var title_f21_56_22402="Patient information: Bacterial vaginosis (The Basics)";
var content_f21_56_22402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15592\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\">",
"         Adult female external genitalia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33570\">",
"         Patient information: Vaginal discharge in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/1/14354\">",
"         Patient information: Vaginal yeast infection (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/43/36529\">",
"         Patient information: Bacterial vaginosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40641\">",
"         Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bacterial vaginosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bacterial-vaginosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1664445898\">",
"      <span class=\"h1\">",
"       What is bacterial vaginosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bacterial vaginosis is an infection in the vagina that can cause bad-smelling vaginal discharge. &ldquo;Vaginal discharge&rdquo; is the term doctors and nurses use to describe any fluid that comes out of the vagina (",
"      <a class=\"graphic graphic_figure graphicRef53704 \" href=\"UTD.htm?0/10/160\">",
"       figure 1",
"      </a>",
"      ). Normally, women have a small amount of vaginal discharge each day. But women with bacterial vaginosis can have a lot of vaginal discharge, or vaginal discharge that smells bad.",
"     </p>",
"     <p>",
"      Bacterial vaginosis is caused by certain bacteria (germs). The vagina normally has different types of bacteria in it. When the amounts or the types of bacteria change, an infection can happen.",
"     </p>",
"     <p>",
"      Women do not catch bacterial vaginosis from having sex. But women who have bacterial vaginosis have a higher chance of catching other infections from their partner during sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445905\">",
"      <span class=\"h1\">",
"       What are the symptoms of bacterial vaginosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women with bacterial vaginosis have no symptoms. When women have symptoms, they often have a &ldquo;fishy-smelling&rdquo; vaginal discharge that they might notice more after sex. The discharge is watery and off-white or gray.",
"     </p>",
"     <p>",
"      Some women can also have other symptoms that are not as common, but can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding from the vagina after sex",
"       </li>",
"       <li>",
"        Itching on the outside of the vagina",
"       </li>",
"       <li>",
"        Pain when urinating or having sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by other conditions. But if you have these symptoms, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445912\">",
"      <span class=\"h1\">",
"       Is there a test for bacterial vaginosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam. He or she will also take a sample of your vaginal discharge, and do lab tests on the sample to look for an infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445919\">",
"      <span class=\"h1\">",
"       How is bacterial vaginosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bacterial vaginosis is treated with medicine. Two different medicines can be used. They are called:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/0/38912?source=see_link\">",
"         Metronidazole",
"        </a>",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?42/59/43952?source=see_link\">",
"         Clindamycin",
"        </a>",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Both of these medicines come in different forms. They can come as a pill or as a gel or cream that a woman puts inside her vagina. Most women have fewer side effects when they use the gel or cream treatment. But you and your doctor or nurse will decide which medicine and which form is right for you.",
"     </p>",
"     <p>",
"      It is important that you take all of the medicine your doctor or nurse prescribes, even if your symptoms go away after a few doses. Taking all of your medicine can help prevent the symptoms from coming back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445926\">",
"      <span class=\"h1\">",
"       Does my sex partner need to be treated if I have bacterial vaginosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Your sex partner does not need to be treated if you have bacterial vaginosis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445933\">",
"      <span class=\"h1\">",
"       What happens if my symptoms come back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms come back, let your doctor or nurse know. You might need treatment with more medicine.",
"     </p>",
"     <p>",
"      Some women get bacterial vaginosis over and over again. These women might take medicine for 3 to 6 months to try to prevent future infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445940\">",
"      <span class=\"h1\">",
"       What if I am pregnant and have symptoms of bacterial vaginosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant and have symptoms of bacterial vaginosis, tell your doctor or nurse. You might need treatment with medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445947\">",
"      <span class=\"h1\">",
"       Can bacterial vaginosis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. You can help prevent bacterial vaginosis by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not douching (douching is when a woman puts a liquid inside her vagina to rinse it out)",
"       </li>",
"       <li>",
"        Not having a lot of sex partners",
"       </li>",
"       <li>",
"        Not smoking",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1664445954\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=see_link\">",
"       Patient information: Vaginal discharge in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=see_link\">",
"       Patient information: Vaginal yeast infection (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/43/36529?source=see_link\">",
"       Patient information: Bacterial vaginosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"       Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/56/22402?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15592 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22402=[""].join("\n");
var outline_f21_56_22402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445898\">",
"      What is bacterial vaginosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445905\">",
"      What are the symptoms of bacterial vaginosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445912\">",
"      Is there a test for bacterial vaginosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445919\">",
"      How is bacterial vaginosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445926\">",
"      Does my sex partner need to be treated if I have bacterial vaginosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445933\">",
"      What happens if my symptoms come back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445940\">",
"      What if I am pregnant and have symptoms of bacterial vaginosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445947\">",
"      Can bacterial vaginosis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1664445954\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\">",
"      Adult female external genitalia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/43/36529?source=related_link\">",
"      Patient information: Bacterial vaginosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=related_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=related_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=related_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_56_22403="Nerves prone to stretch or compression in lithotomy";
var content_f21_56_22403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nerves prone to stretch or compression in lithotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 659px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sciatic and femoral nerve stretching occurs with hip flexion and external rotation. The fibular (peroneal) nerve is superficial in the proximal leg and this site is prone to compression. The posterior tibial nerve is stretched with ankle dorsiflexion and is at risk when the foot is in stirrups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22403=[""].join("\n");
var outline_f21_56_22403=null;
var title_f21_56_22404="Penicilloyl-polylysine: Pediatric drug information";
var content_f21_56_22404=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicilloyl-polylysine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"    see \"Penicilloyl-polylysine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pre-Pen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=see_link\">",
"      see \"Penicilloyl-polylysine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Benzylpenicilloyl polylysine should always be applied first via the puncture technique.",
"     <b>",
"      Do not administer intradermally to patients who have positive reactions to a puncture test.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Puncture scratch test: Apply a small drop of the skin test solution using a 22-28 gauge needle and to make a single shallow puncture of the epidermis through the drop of solution. A positive reaction consists of a pale wheal surrounding the puncture site which develops within 10 minutes and ranges from 5-15 mm or more in diameter (wheal may be surrounded by erythema and variable degrees of itching). If a positive response is evident, the solution should be wiped off immediately. If the puncture test is negative or equivocal (&lt;5 mm wheal, with little or no erythema and no itching) 15 minutes following the puncture test, an intradermal test may be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intradermal test: Using a 0.5 to 1 mL tuberculin syringe with a",
"     <sup>",
"      3",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     to",
"     <sup>",
"      5",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     inch, 26- to 30-gauge short bevel needle; inject a volume of skin test solution sufficient to raise a small intradermal bleb ~3 mm in diameter intradermally and duplicate at least 2 cm apart. A control of 0.9% sodium chloride or allergen-diluting solution should be injected at least 5 cm from the antigen test site. Most skin responses to the intradermal test will develop within 5-15 minutes. A response to the skin test is read at 20 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interpretation of intradermal test:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     (-) Negative: No increase in size of original bleb or no greater reaction compared to the control site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     (&plusmn;) Ambiguous: Wheal only slightly larger than original bleb with or without erythematous flare and slightly larger than control site;",
"     <b>",
"      or",
"     </b>",
"     discordance between duplicate test sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     (+) Positive: Itching and marked increase in size of original bleb to &ge;5 mm. Wheal may exhibit pseudopods and be &gt;20 mm in diameter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Control site should be reactionless. If wheal &gt;2-3 mm develops at control site, repeat the test. If same reaction occurs, consultation is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pre-Pen&reg;: 6 x 10",
"     <sup>",
"      -5",
"     </sup>",
"     M (0.25 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Puncture test: Administer initially by puncture technique on the inner volvar aspect of the forearm; observe 15 minutes for reaction. If negative reaction, follow with an intradermal injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intradermal test: Do",
"     <b>",
"      not",
"     </b>",
"     administer intradermally to patients with a positive reaction to a puncture test (wheal of 5-15 mm or more in diameter). Administer the intradermal test on the upper, outer arm, below the deltoid muscle in the event a severe hypersensitivity reaction occurs and a tourniquet needs to be applied. During the skin test, immediate treatment with epinephrine should also be available. Observe 20 minutes for reaction.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); discard if left at room temperature for longer than 1 day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in assessing the risk of administering penicillin (penicillin G or benzylpenicillin) in patients suspected of a clinical penicillin hypersensitivity [FDA approved in pediatric patients (age not specified) and adults]. Has also been used as an adjunct in assessment of hypersensitivity to other beta-lactam antibiotics (penicillins and cephalosporins) to determine the safety of penicillin administration in patients with a history of reaction to cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, pruritus, erythema, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Inflammation (intense; at skin test site), wheal (locally)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Systemic allergic reactions (including anaphylaxis; rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic or marked local reaction to a previous administration of benzylpenicilloyl polylysine skin test; patients with a known severe  hypersensitivity to penicillin should not be tested.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare  systemic allergic reactions, including anaphylaxis, have been associated with penicillin skin testing. Penicillin skin testing should only be performed by skilled medical personnel under direct supervision of a physician, and testing should be performed only in an appropriate healthcare setting prepared for the immediate treatment with epinephrine. To decrease the risk of a systemic allergic reaction, the manufacturer recommends puncture skin testing prior to intradermal testing. Patients with a reliable history of a severe life-threatening penicillin allergy, including Stevens-Johnson syndrome or TEN, should",
"     <b>",
"      not",
"     </b>",
"     receive penicillin skin testing. Responses to skin testing may be attenuated by concurrent administration of antihistamines. Consider delaying testing until these medications can be withheld to allow time for their effects to dissipate; hydroxyzine and diphenhydramine should be discontinued for at least 4 days before skin testing (Boguniewicz, 1995).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     According to the manufacturer, a negative skin test is associated with an incidence of immediate allergic reactions of &lt;5% after penicillin administration and a positive skin test may indicate &gt;50% incidence of allergic reaction occurring after penicillin administration. Adequate penicillin skin testing should ideally involve reagents of both the major antigenic determinant (penicilloyl-polylysyine) and minor determinants (penicilloate or penilloate). Benzylpenicilloyl polylysine alone does not identify those patients who react to a minor antigenic determinant. The minor determinant mixture (MDM) is not commercially available in the U.S.; however, diluted penicillin G (concentration: 10,000 U/mL) has been used as a minor determinant for skin testing purposes (Bernstein, 2008). Penicillin skin testing does not predict the occurrence of late reactions (eg, Type II, III, IV, or idiopathic reactions).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin; EPINEPHrine (Nasal); Isometheptene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Naphazoline (Nasal); Naphazoline (Ophthalmic); Oxymetazoline (Nasal); Phenylephrine (Nasal); Phenylephrine (Ophthalmic); Phenylephrine (Topical); Propylhexedrine; Xylometazoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: May diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with benzylpenicilloyl polylysine. The Centers for Disease Control and Prevention (CDC) states that penicillin skin testing may be useful in assessing suspected penicillin hypersensitivity in pregnant women diagnosed with syphilis (of any stage) due to a lack of proven alternatives to the use of penicillin in this population (CDC, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12726989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe 15 minutes (puncture) or 20 minutes (intradermal) for reaction.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzylpenicilloyl polylysine, a conjugate of the benzylpenicilloyl structural group (hapten) and the poly-l-lysine carrier (protein), is an antigen which reacts with  benzylpenicilloyl IgE antibodies to elicit the release of chemical mediators, thereby producing type I (immediate or accelerated) urticarial reactions in patients hypersensitive to penicillins.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillin skin testing is the preferred method of evaluating patients with possible penicillin specific IgE-mediated (Type I) immediate hypersensitivity reactions, when performed using the appropriate major and minor determinant reagents. Testing detects the presence or absence of penicillin-specific IgE antibodies; therefore, it is not useful to detect non-IgE mediated reactions. Patients testing positive to benzylpenicilloyl polylysine possess IgE antibodies against the benzylpenicilloyl structural group (B-lactam ring). The possibility exists for patients to have selective IgE antibodies directed against the R-group side chain structure of certain penicillins, rather than the core beta-lactam structure. Therefore, these patients may test negative to the penicillin major and minor determinants, but be allergic to semisynthetic penicillins (eg, amoxicillin, ampicillin) only and tolerate other penicillin compounds (Bernstein, 2008). Skin testing has also been used in some centers to determine safety of penicillin administration in patients with prior reactions to cephalosporins.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein IL, Li JT, Bernstein DI, et al, \"Allergy Diagnostic Testing: An Updated Practice Parameter,\"",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2008, 100(3 Suppl 3):1-148.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/56/22404/abstract-text/18431959/pubmed\" id=\"18431959\" target=\"_blank\">",
"        18431959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DYM, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/56/22404/abstract-text/7761188 /pubmed\" id=\"7761188 \" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 55(RR-11):1-94. Available at",
"      <a href=\"file://www.cdc.gov/std/treatment/2006/rr5511.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/std/treatment/2006/rr5511.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macy E, Mangat R, and Burchette RJ, \"Penicillin Skin Testing in Advance of Need: Multiyear Follow-Up in 568 Test Result-Negative Subjects Exposed to Oral Penicillins,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2003, 111(5):1111-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/56/22404/abstract-text/12743578/pubmed\" id=\"12743578\" target=\"_blank\">",
"        12743578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salkind AR, Cuddy PG, and Foxworth JW, \"The Rational Clinical Examination. Is This Patient Allergic to Penicillin? An Evidence-Based Analysis of the Likelihood of Penicillin Allergy,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2498-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/56/22404/abstract-text/11368703/pubmed\" id=\"11368703\" target=\"_blank\">",
"        11368703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wendel GD Jr, Stark BJ, Jamison RB, et al, \"Penicillin Allergy and Desensitization in Serious Infections During Pregnancy,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 312(19):1229-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/56/22404/abstract-text/3921835/pubmed\" id=\"3921835\" target=\"_blank\">",
"        3921835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16454 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22404=[""].join("\n");
var outline_f21_56_22404=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045544\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045538\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140299\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140287\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045547\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045541\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045546\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140320\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045549\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045537\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298849\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140295\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140297\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12726989\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045536\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045550\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/56/17285?source=related_link\">",
"      Penicilloyl-polylysine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_56_22405="Ranitidine: Patient drug information";
var content_f21_56_22405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ranitidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     see \"Ranitidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"     see \"Ranitidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zantac 150&reg; [OTC];",
"     </li>",
"     <li>",
"      Zantac 75&reg; [OTC];",
"     </li>",
"     <li>",
"      Zantac&reg;;",
"     </li>",
"     <li>",
"      Zantac&reg; EFFERdose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Reducer;",
"     </li>",
"     <li>",
"      Apo-Ranitidine&reg;;",
"     </li>",
"     <li>",
"      CO Ranitidine;",
"     </li>",
"     <li>",
"      Dom-Ranitidine;",
"     </li>",
"     <li>",
"      Myl-Ranitidine;",
"     </li>",
"     <li>",
"      Mylan-Ranitidine;",
"     </li>",
"     <li>",
"      Nu-Ranit;",
"     </li>",
"     <li>",
"      PHL-Ranitidine;",
"     </li>",
"     <li>",
"      PMS-Ranitidine;",
"     </li>",
"     <li>",
"      Ranitidine Injection, USP;",
"     </li>",
"     <li>",
"      RAN&trade;-Ranitidine;",
"     </li>",
"     <li>",
"      ratio-Ranitidine;",
"     </li>",
"     <li>",
"      Riva-Ranitidine;",
"     </li>",
"     <li>",
"      Sandoz-Ranitidine;",
"     </li>",
"     <li>",
"      ScheinPharm Ranitidine;",
"     </li>",
"     <li>",
"      Teva-Ranitidine;",
"     </li>",
"     <li>",
"      Zantac 75&reg;;",
"     </li>",
"     <li>",
"      Zantac Maximum Strength Non-Prescription;",
"     </li>",
"     <li>",
"      Zantac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and sour stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ranitidine hydrochloride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if you are taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694823",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drop the effervescent tablet in 1 teaspoon (5 mL) of water. Drink it when it melts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The OTC tablet may be taken on an as needed basis. Do not take more often than every 12 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11022 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22405=[""].join("\n");
var outline_f21_56_22405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217321\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217322\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019854\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019856\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019855\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019860\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019861\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019863\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019858\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019859\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019864\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019865\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=related_link\">",
"      Ranitidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=related_link\">",
"      Ranitidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_56_22406="Mycophenolate: Patient drug information";
var content_f21_56_22406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mycophenolate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     see \"Mycophenolate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     see \"Mycophenolate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CellCept&reg;;",
"     </li>",
"     <li>",
"      Myfortic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mycophenolate;",
"     </li>",
"     <li>",
"      CellCept&reg;;",
"     </li>",
"     <li>",
"      CO Mycophenolate;",
"     </li>",
"     <li>",
"      JAMP-Mycophenolate;",
"     </li>",
"     <li>",
"      Myfortic&reg;;",
"     </li>",
"     <li>",
"      Mylan-Mycophenolate;",
"     </li>",
"     <li>",
"      Novo-Mycophenolate;",
"     </li>",
"     <li>",
"      Sandoz-Mycophenolate;",
"     </li>",
"     <li>",
"      Sandoz-Mycophenolate Mofetil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will have more chance of getting infections. Avoid crowds and people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mycophenolate may raise your chance of getting lymphoma or skin cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug if you are pregnant. Use during pregnancy may cause birth defects. A pregnancy test will be done right before starting this drug and repeated 8 to 10 days later to show that you are NOT pregnant. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lupus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692121",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat uveitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be used to treat graft-versus-host-disease (GVHD).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat myasthenia gravis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3558764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat immune linked hepatitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mycophenolate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to polysorbate 80.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids, cholestyramine, colestipol, or iron within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The chance of cancer is higher after using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a chance of skin cancer. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust 1 month before care begins, during care, and for 6 weeks after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given. Hold tube feeding a couple of hours before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10882 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22406=[""].join("\n");
var outline_f21_56_22406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198686\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028706\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028708\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028707\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028712\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028713\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028715\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028710\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028711\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028716\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028717\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=related_link\">",
"      Mycophenolate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=related_link\">",
"      Mycophenolate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_56_22407="Ventriculophasic block tutorial";
var content_f21_56_22407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1049px;\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Ventriculophasic sinus arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 101px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ventriculophasic sinus arrhythmia is characterized by episodic or permanent failure of conduction throught the atrioventricular (AV) node. In contrast to the typical second or third degree AV block, the PP intervals are not constant; the two P waves surrounding a QRS complex have a shortened interval or occur at a faster rate when compared to two P waves that occur sequentially without an intervening QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCABnAcgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3W6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jii6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/ANNs23QBflX733uB83Xn36jikn/X3eZ7EY7adun+H+7/AF+WP9p3eL9e/wBNs23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFRTen9d/Upx1Wnbp/h/u/1+WP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxQn733f1uCj7q0/D/D/d/r8i6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4rYurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4ob1j/XT1CEdNu3T/D/d/r8ti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiib91/1+oUo+9HTt0/w/wB3+vyZ4x8Y6X4Ztri41rUVjtpYdvnQ2M0yDkjDNHuCHLgDdjOeOho0DxhpfiuyvrvRNRW4tTCFEsljNAsvLjEZkxuIIIO3OOM478r+0bcb/hH4mH2u1k3R2gwg+9i6TgfMeR1PXr2qH9nmbb8F9JX7TbpmC4XYw+Y/6TPwPm68+nccetoxi37Tlt0XT08v0Oz+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4qKb0/rv6mzjqtO3T/AA/3f6/LH8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jihP3vu/rcFH3Vp+H+H+7/X5F1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/AGnd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6hCOm3bp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFE37r/r9QpR96Onbp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf8Aptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWn/AF93mTGO2nbp/h/u/wBflj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxUU3p/Xf1KcdVp26f4f7v9flj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcUJ+9939bgo+6tPw/w/3f6/Iurnd9r/ANNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKG9Y/109QhHTbt0/w/3f6/LYurnd9r/wBNs23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4om/df9fqFKPvR07dP8P8Ad/r8ti6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/wDTbNt0AX5V+997gfN159+o4ournd9r/wBNs23QBflX733uB83Xn36jirT/AK+7zJjHbTt0/wAP93+vyx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4qKb0/rv6lOOq07dP8P93+vyx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKE/e+7+twUfdWn4f4f7v8AX5F1c7vtf+m2bboAvyr9773A+brz79RxWP8Aad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6hCOm3bp/h/u/wBflsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFE37r/r9QpR96Onbp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFWn/X3eZMY7adun+H+7/X5crr/iOy0LX9fvdSvk+zf2XaK729pLPgB7wkkR7ioAByx4GRnHGW6d8SvD2vWmpXWkalPfW8cIR3g0i7IY5xsX5eW/eKcDJwc4wCap/EG53WHxD/ANNs23eF1Hyr97i94HzdeffqOK4f9k2XZ8NteXz4Y91/INrjl/3MfC8jn8+tTT2/rv6kyb9oo26Lp6eR1mqfEvw34q8OeJ7bQdX+2ynSplYpptyiD91KQGdgFQnBxuPJ4GTxXol1c7vtf+m2bboAvyr9773A+brz79RxXyv+zlLs8C/FJfPhj3aag2uOX/dXPC8jn8+tfVF1c7vtf+m2bboAvyr9773A+brz79RxQn77+QUW504trr2/w+X9fkXVzu+1/wCm2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxWP8Aad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxSb1j/XT1NIR027dP8P93+vy2Lq53fa/9Ns23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiib91/wBfqFKPvR07dP8AD/d/r8ti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKLq53fa/8ATbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jirT/r7vMmMdtO3T/D/AHf6/LH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4qKb0/rv6lOOq07dP8P93+vyx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jihP3vu/rcFH3Vp+H+H+7/X5F1c7vtf+m2bboAvyr9773A+brz79RxRRdXO77X/ptm26AL8q/e+9wPm68+/UcUV0UjtwKsn8vy9EZF0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UUXR15vtn/FQeH23QBfl02T5vvcD/AEnrz79RWvdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFYpf193mcUb6adun+H+6cmX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxzq3R15vtn/FQeH23QBfl02T5vvcD/SevPv1FJ9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQ2/rv6lO91p26f4f7v8AX5cn41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj11bo6832z/ioPD7boAvy6bJ833uB/pPXn36ik8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFC+L7v63BX5Vp+H+H+7/X5ZF0deb7Z/xUHh9t0AX5dNk+b73A/wBJ68+/UVlF9abxTrgXXdCaU6XahmGnvtcb7rCqPtHDDnJyc7hwMc9ZdXO77X/ptm26AL8q/e+9wPm68+/UcVj/AGnd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUPdf109Qhe23bp/h/u/wBfkt0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UVleNX1r/AIRbxIZtd0KWI6XKHWPT3VnGyTKqTcHDc9cHqOPXrLq53fa/9Ns23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFE/hf9fqFK/NHTt0/w/3f6/Lz/wCPb63deBNV0sXttqk99HAI7fTNGuGZ9k6sR5iyusZA5+YfMOBzUPwM/ty2+G0Ol/a7bTJ7SCRZLXUdHuFcb5pmAV2lRXJDZ+UHG5Qeevr11c7vtf8Aptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWv6/q5lGHvqdu3T0/u/1+XJl9abxTrgXXdCaU6XahmGnvtcb7rCqPtHDDnJyc7hwMc6t0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RSfad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVENv67+pq73Wnbp/h/u/1+XJ+NX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49dW6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKTx3c7vCHij/AE2zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcUL4vu/rcFflWn4f4f7v9flkXR15vtn/ABUHh9t0AX5dNk+b73A/0nrz79RWUX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxz1l1c7vtf+m2bboAvyr9773A+brz79RxWP9p3eL9e/wBNs23aVaL8q/e/eXfA+brz79RxQ91/XT1CF7bdun+H+7/X5LdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVleNX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49esurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcUT+F/1+oUr80dO3T/D/AHf6/Jbo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/4qDw+26AL8umyfN97gf6T159+orXurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/wDTbNt0AX5V+997gfN159+o4q0v6+7zJjfTTt0/w/3Tky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jioht/Xf1Kd7rTt0/w/3f6/Lk/Gr61/wi3iQza7oUsR0uUOsenurONkmVUm4OG564PUceurdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FJ47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKF8X3f1uCvyrT8P8AD/d/r8si6OvN9s/4qDw+26AL8umyfN97gf6T159+orKL603inXAuu6E0p0u1DMNPfa433WFUfaOGHOTk53DgY56y6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4oe6/rp6hC9tu3T/D/d/r8lujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKyvGr61/wAIt4kM2u6FLEdLlDrHp7qzjZJlVJuDhueuD1HHr1l1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiifwv+v1Clfmjp26f4f7v9fkt0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RRdHXm+2f8AFQeH23QBfl02T5vvcD/SevPv1Fa91c7vtf8Aptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWl/X3eZMb6adun+H+6cmX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxzq3R15vtn/FQeH23QBfl02T5vvcD/AEnrz79RSfad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFRDb+u/qU73Wnbp/h/u/1+XJ+NX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49dW6OvN9s/4qDw+26AL8umyfN97gf6T159+opPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFC+L7v63BX5Vp+H+H+7/X5ZF0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RWUX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxz1l1c7vtf+m2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFD3X9dPUIXtt26f4f7v9fkt0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RWV41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj16y6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcUT+F/wBfqFK/NHTt0/w/3f6/Jbo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/4qDw+26AL8umyfN97gf6T159+orXurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jirS/r7vMmN9NO3T/D/AHTzD4h3erRweMYH1SwvJ73QorRY7HR55mmLi8CooSVzGc7gXbKjcuQP4uJ+AE2seGfBOu2d55+lSNO1x5F3oF3cPKpWNMoyMoJyfugEgAt0BI9t+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKiG39d/UTh76lbounp/d/r8vlT4MWuteH/AAx48tL+C40r+0NPO1b3SbhhOEhnLBZQVSI4bGXzksMAng/Sl0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RSeO7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/02zbdAF+Vfvfe4HzdeffqOKa1k/l/W4U4ckEkuvb/AA/3f6/LIujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKyi+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOesurnd9r/ANNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKT3X9dPUuF7bdun+H+7/X5LdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVleNX1r/hFvEhm13QpYjpcodY9PdWcbJMqpNwcNz1weo49esurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcUT+F/1+oUr80dO3T/D/AHf6/Jbo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/4qDw+26AL8umyfN97gf6T159+orXurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/wDTbNt0AX5V+997gfN159+o4q0v6+7zJjfTTt0/w/3Tky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jioht/Xf1Kd7rTt0/w/3f6/Lk/Gr61/wi3iQza7oUsR0uUOsenurONkmVUm4OG564PUceurdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FJ47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKF8X3f1uCvyrT8P8AD/d/r8si6OvN9s/4qDw+26AL8umyfN97gf6T159+oorXurnd9r/02zbdAF+Vfvfe4HzdeffqOKK3pRT/AOH/AOCduBbSenbp5eiMi68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FF14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqK17q53fa/8ATbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKzV+/wDWnmcEVHTTt/7b/d/r8uTPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHrq3XjDQT9s/4qnw+26AD5bmP5vv8AA/edeffqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiog3bf+r+pTUbrTt/7b/d/r8uT8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHrq3XjDQT9s/4qnw+26AD5bmP5vv8D95159+opPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFCvzb9v63BKPKtP693+7/X5ZF14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqKyj4r0X/hKdclPiXQjFJpdrGri4Ta5D3RKqd/3huGev3hx69ZdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcUNu61/q3qEFG23b/wBt/u/1+S3XjDQT9s/4qnw+26AD5bmP5vv8D95159+orK8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHr1l1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiid+V6/194U1Hmjp2/wDbf7v9fkt14w0E/bP+Kp8PtugA+W5j+b7/AAP3nXn36ii68YaCftn/ABVPh9t0AHy3Mfzff4H7zrz79RWvdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/wCm2bboAvyr9773A+brz79RxVq/f+tPMmKjpp2/9t/u/wBflyZ8V6L/AMJTrkp8S6EYpNLtY1cXCbXIe6JVTv8AvDcM9fvDj11brxhoJ+2f8VT4fbdAB8tzH833+B+868+/UUn2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxUQbtv8A1f1Kajdadv8A23+7/X5cn418V6LceFvEkUPiXQppZdLljRI7hC0hKSAKoDn5uffqOPXVuvGGgn7Z/wAVT4fbdAB8tzH833+B+868+/UUnju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jihX5t+39bglHlWn9e7/d/r8si68YaCftn/ABVPh9t0AHy3Mfzff4H7zrz79RWUfFei/wDCU65KfEuhGKTS7WNXFwm1yHuiVU7/ALw3DPX7w49esurnd9r/ANNs23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKG3da/wBW9Qgo227f+2/3f6/JbrxhoJ+2f8VT4fbdAB8tzH833+B+868+/UVleNfFei3HhbxJFD4l0KaWXS5Y0SO4QtISkgCqA5+bn36jj16y6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFE78r1/r7wpqPNHTt/7b/d/r8luvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRdeMNBP2z/iqfD7boAPluY/m+/wP3nXn36ite6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jirV+/8AWnmTFR007f8Atv8Ad/r8uTPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHrq3XjDQT9s/wCKp8PtugA+W5j+b7/A/edeffqKT7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiog3bf+r+pTUbrTt/7b/d/r8uT8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHrq3XjDQT9s/4qnw+26AD5bmP5vv8D95159+opPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/wCm2bboAvyr9773A+brz79RxQr82/b+twSjyrT+vd/u/wBflkXXjDQT9s/4qnw+26AD5bmP5vv8D95159+orKPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHr1l1c7vtf+m2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFDbutf6t6hBRtt2/wDbf7v9fkt14w0E/bP+Kp8PtugA+W5j+b7/AAP3nXn36isrxr4r0W48LeJIofEuhTSy6XLGiR3CFpCUkAVQHPzc+/UcevWXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKJ35Xr/AF94U1Hmjp2/9t/u/wBfkt14w0E/bP8AiqfD7boAPluY/m+/wP3nXn36ii68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1Fa91c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/ptm26AL8q/e+9wPm68+/UcVav3/rTzJio6adv/bf7v9flyZ8V6L/wlOuSnxLoRik0u1jVxcJtch7olVO/7w3DPX7w49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FJ9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQbtv/V/UpqN1p2/9t/u/wBflyfjXxXotx4W8SRQ+JdCmll0uWNEjuELSEpIAqgOfm59+o49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FJ47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4oV+bft/W4JR5Vp/Xu/wB3+vyyLrxhoJ+2f8VT4fbdAB8tzH833+B+868+/UVlHxXov/CU65KfEuhGKTS7WNXFwm1yHuiVU7/vDcM9fvDj16y6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiht3Wv9W9Qgo227f+2/3f6/JbrxhoJ+2f8VT4fbdAB8tzH833+B+868+/UVleNfFei3HhbxJFD4l0KaWXS5Y0SO4QtISkgCqA5+bn36jj16y6ud32v/TbNt0AX5V+997gfN159+o4rH8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxRO/K9f6+8KajzR07f8Atv8Ad/r8luvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRdeMNBP2z/iqfD7boAPluY/m+/wAD95159+orXurnd9r/ANNs23QBflX733uB83Xn36jii6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKtX7/ANaeZMVHTTt/7b/d/r8uTPivRf8AhKdclPiXQjFJpdrGri4Ta5D3RKqd/wB4bhnr94ceurdeMNBP2z/iqfD7boAPluY/m+/wP3nXn36ik+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/AE2zbdAF+Vfvfe4HzdeffqOKiDdt/wCr+pTUbrTt/wC2/wB3+vy5Pxr4r0W48LeJIofEuhTSy6XLGiR3CFpCUkAVQHPzc+/UceurdeMNBP2z/iqfD7boAPluY/m+/wAD95159+opPHdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxQr82/b+twSjyrT+vd/u/1+WRdeMNBP2z/iqfD7boAPluY/m+/wAD95159+orKPivRf8AhKdclPiXQjFJpdrGri4Ta5D3RKqd/wB4bhnr94cevWXVzu+1/wCm2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFDbutf6t6hBRtt2/9t/u/wBfkt14w0E/bP8AiqfD7boAPluY/m+/wP3nXn36isrxr4r0W48LeJIofEuhTSy6XLGiR3CFpCUkAVQHPzc+/UcevWXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiid+V6/194U1Hmjp2/9t/u/1+S3XjDQT9s/4qnw+26AD5bmP5vv8D95159+oouvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RWvdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFWr9/608yYqOmnb/wBt/u/1+XJnxXov/CU65KfEuhGKTS7WNXFwm1yHuiVU7/vDcM9fvDj11brxhoJ+2f8AFU+H23QAfLcx/N9/gfvOvPv1FJ9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQbtv/V/UpqN1p2/9t/u/1+XJ+NfFei3HhbxJFD4l0KaWXS5Y0SO4QtISkgCqA5+bn36jj11brxhoJ+2f8VT4fbdAB8tzH833+B+868+/UUnju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/8ATbNt0AX5V+997gfN159+o4oV+bft/W4JR5Vp/Xu/3f6/LIuvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRWvdXO77X/ptm26AL8q/e+9wPm68+/UcUVvT5ns/6+87cDypPTt+Xogurnd9r/02zbdAF+Vfvfe4HzdeffqOKLq53fa/9Ns23QBflX733uB83Xn36jisi6OvN9s/4qDw+26AL8umyfN97gf6T159+ooujrzfbP8AioPD7boAvy6bJ833uB/pPXn36is1L+vu8zgjBafLp/h/uifad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcmX1pvFOuBdd0JpTpdqGYae+1xvusKo+0cMOcnJzuHAxzL4r1PXtJ0DXtT/ALb8P3H2TTpJ/LXT5F83YkjbAftBwTjGcHqOPWIS0/rv6jlFKzfl08o/3f6/KlP4ttfGHwq1vXLCYQ215pVyqRXMQSU7RMhGBIwBypPU8EcV2l1c7vtf+m2bboAvyr9773A+brz79RxXh3wwOpj9naXytU0uKzOl3oNvLaM0pHmXGVD+cBuOTg7ONw4OOfWro6832z/ioPD7boAvy6bJ833uB/pPXn36ine038v63FCN4Rf6f4f7pr3Vzu+1/wCm2bboAvyr9773A+brz79RxWP9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFLdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVlF9abxTrgXXdCaU6XahmGnvtcb7rCqPtHDDnJyc7hwMcpvVf109SoQVvu6f4f7v9fl1l1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4pbo6832z/AIqDw+26AL8umyfN97gf6T159+orK8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx6k37r/r9QpQXNH5dP8P93+vy6TWtVgsNP1W9vNRs1tYLNpZXVCfkUOTgBicgZ6Z6jj1S31a31TTjfWWo2k1reWaSxOIyhkRgzLgFsg4I4IzyOK4f4u6pqulfDzxTc3utaPc28mn/AGVkttOcO5lLRAKTckDBkBJwcDnBxgz+ATrR+HehCHW9ESI6HaKkb6e7OB5PCEi4GWGeTgdegq0/6/pmUV7/AC+S6en906L7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4rky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/4qDw+26AL8umyfN97gf6T159+oqIPT+u/qauCuvl0/wAP93+vyTx3c7vCHij/AE2zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVyfjV9a/wCEW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj11bo6832z/ioPD7boAvy6bJ833uB/pPXn36ihP3vu/rcFBcq/wAv8P8Ad/r8te6ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jilujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKyi+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GORvVf109QhBW+7p/h/u/wBfl0i6ta339pfY9W0268pTby+QwbbIu7MZw5w4yMg88jj1z/Hdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcV5l8Eb6/1PTvHd/pOtaStrea7dzK82nyE3G4A7kBmUoCCMKQxGeSa7nxq+tf8It4kM2u6FLEdLlDrHp7qzjZJlVJuDhueuD1HHq5v3X/AF+pNCKbi/Tp/h/u/wBfl1l1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFZF0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UUXR15vtn/FQeH23QBfl02T5vvcD/AEnrz79RVKX9fd5hGC0+XT/D/dE+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/4qDw+26AL8umyfN97gf6T159+oqIPT+u/qU4K6+XT/AA/3f6/JPHdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxXJ+NX1r/AIRbxIZtd0KWI6XKHWPT3VnGyTKqTcHDc9cHqOPXVujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKE/e+7+twUFyr/AC/w/wB3+vy17q53fa/9Ns23QBflX733uB83Xn36jisf7Tu8X69/ptm27SrRflX737y74HzdeffqOKW6OvN9s/4qDw+26AL8umyfN97gf6T159+orKL603inXAuu6E0p0u1DMNPfa433WFUfaOGHOTk53DgY5G9V/XT1CEFb7un+H+7/AF+XWXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKW6OvN9s/4qDw+26AL8umyfN97gf6T159+orK8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx6k37r/r9QpQXNH5dP8P8Ad/r8usurnd9r/wBNs23QBflX733uB83Xn36jii6ud32v/TbNt0AX5V+997gfN159+o4rIujrzfbP+Kg8PtugC/Lpsnzfe4H+k9effqKLo6832z/ioPD7boAvy6bJ833uB/pPXn36irUv6+7zJjBafLp/h/uifad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVyZfWm8U64F13QmlOl2oZhp77XG+6wqj7Rww5ycnO4cDHOrdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FRB6f139SnBXXy6f4f7v8AX5J47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOK5Pxq+tf8ACLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx66t0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RQn733f1uCguVf5f4f7v9flr3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/AE2zbdpVovyr9795d8D5uvPv1HFLdHXm+2f8VB4fbdAF+XTZPm+9wP8ASevPv1FZRfWm8U64F13QmlOl2oZhp77XG+6wqj7Rww5ycnO4cDHI3qv66eoQgrfd0/w/3f6/LrLq53fa/wDTbNt0AX5V+997gfN159+o4rH8d3O7wh4o/wBNs23aVMvyr9793JwPm68+/UcUt0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RWV41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj1Jv3X/X6hSguaPy6f4f7v9fl1l1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/ptm26AL8q/e+9wPm68+/UcVkXR15vtn/FQeH23QBfl02T5vvcD/SevPv1FF0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RVqX9fd5kxgtPl0/wAP90T7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4rky+tN4p1wLruhNKdLtQzDT32uN91hVH2jhhzk5Odw4GOdW6OvN9s/4qDw+26AL8umyfN97gf6T159+oqIPT+u/qU4K6+XT/D/d/r8k8d3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFcn41fWv+EW8SGbXdCliOlyh1j091Zxskyqk3Bw3PXB6jj11bo6832z/ioPD7boAvy6bJ833uB/pPXn36ihP3vu/rcFBcq/y/w/3f6/LXurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4pbo6832z/ioPD7boAvy6bJ833uB/pPXn36isovrTeKdcC67oTSnS7UMw099rjfdYVR9o4Yc5OTncOBjkb1X9dPUIQVvu6f4f7v9fl1l1c7vtf8Aptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4pbo6832z/AIqDw+26AL8umyfN97gf6T159+orK8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx6k37r/r9QpQXNH5dP8P93+vy6y6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKyLo6832z/ioPD7boAvy6bJ833uB/pPXn36ii6OvN9s/wCKg8PtugC/Lpsnzfe4H+k9effqKtS/r7vMmMFp8un+H+6J9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcVyZfWm8U64F13QmlOl2oZhp77XG+6wqj7Rww5ycnO4cDHOrdHXm+2f8VB4fbdAF+XTZPm+9wP9J68+/UVEHp/Xf1KcFdfLp/h/u/1+SeO7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/wBNs23QBflX733uB83Xn36jiuT8avrX/CLeJDNruhSxHS5Q6x6e6s42SZVSbg4bnrg9Rx66t0deb7Z/xUHh9t0AX5dNk+b73A/0nrz79RQn733f1uCguVf5f4f7v9flr3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFFZF0deb7Z/wAVB4fbdAF+XTZPm+9wP9J68+/UUVvSk+39feduBgknr2/L0Rr3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxWHf8Ajjw3G12svi7w2Ga3AwbyIbh8/A/edfz6imXXjzwuftn/ABWPhlt0AHy3sXzff4H7zrz79RULX+vTzPM5oxaT8v8A23+7/X5T/ad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxVf4l3O7wD4x/02zbdotwPlX737qXgfN159+o4rhvGHxi8O+HPF2oFbwa3He6Xbp5ujpHcJHskuMh280BT+8B79eQOMt+NXjzRtV+E/iA6D4q0u4ubq1tgsVrOEneNpl3Ls37x8jMGUjOCQQOaiF7f1/mTVnBx07fov7v8AX5cv8Bb2Z/gH4zimvV8uJbuKKOZi2FNuG2pkjaNzscAdWJ78/Qd1c7vtf+m2bboAvyr9773A+brz79RxXz34G1rQvDWifFDwhHqFjaNI97c6cplEkV1bvFtjWKXeQz4C/KSW57lWx7Hq3j/wvaRajJceLvDxCW2WWO5RnYAOdqqHJLewBJyMD1ad56eRcbRppy6P/wCR8v6/Lobq53fa/wDTbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jivMta+Ld/wCKNT1Ox+H+p+HLbT4rLbNq2tM1sJJGB2rbxsdxZck5ZSMjkAbd7/AHxK8zXvEVh451rQrTVrawgtRdxzqbbUUjaY+bHJkIGImXK9c5+UYZVHq1/X6ihJWu1pprbT7PkexXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKLjxjoEi3TL4q8Pur24wVuo/nHzcD95159+orkviR8T/CdrpWuaVJ4n02a+vNMeKJbaJ5lZmWRVUuhZUOT/ABHoQTgclSd4tL+vxLglBxclZaf+2/3f6/I/aNuN/wAI/Ew+12sm6O0GEH3sXScD5jyOp69e1SfAvVbnUPhBo0t7e27SrZNbAMgDFIpZY0QYI5CKozjJ4zk8nC+PniPTNY0DTdHtvEmmTWeqarZWl/8AY5omYW+6Riclm27WVDu+meMgx/s/+LNEtfhRbadda7plneWkc0M9tdSCKQEzTOAAzDOQ4OQCOcdQatNWvcyjTaq7dF09PL9D0r7Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiuRl8XaFH4m124l8T6AIH0u1jEhuYwrkSXWVU+ZjcNy+v3l49eL8WfGe9udS1mw8CWuj6oltGkEmpXt9FawM+W3CJHkUygDI3K3XBwRtLRB6X/AK/M1n7skra2Wltdo/3T0rx3c7vCHij/AE2zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcV4XbfGSfW9J8RaX4tg03SLrU9Jml0xoJRNHIhjfbBIwc7J+ejYJJA2qdob1268YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FCa5t+39bjhHmirLZ9v8P9017q53fa/wDTbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jim3/AI08OxrdtL4s8OhWgC5N3GA33/lH7zr+fUcVzfiLxvpllN4v1PT/ABDoFzKmgxNbATKyTyIbthGuJOTyuQDn5h6jI38L/rb1CK5U7rZLp/h/u/1+XnP7IuqSnw54t0xpbaKCKSKdd6ne7SI6sAdwHSJccdzXtnju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK8L/AGbLvSfDD+LrW58QaXGLmx064QzyJGZC8DyPGuX5KNJsPXkcgdK9g8a+K9FuPC3iSKHxLoU0sulyxokdwhaQlJAFUBz83Pv1HHqVJe69TPBxlJRduvbzXl/X5dZdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcJ47+Lnhrw0ArapDq895H5awaSi3DhQHyx/eYUDI6nJzwDg4qeAfjBpHi/StQl1K6sdB1OKPy5rK8kClh85UxszLuBB54yCcEYwWpP+v6Y4pXSt26en93+vy677Tu8X69/ptm27SrRflX737y74HzdeffqOK2Lq53fa/9Ns23QBflX733uB83Xn36jiuTPivRf+Ep1yU+JdCMUml2sauLhNrkPdEqp3/eG4Z6/eHHrq3XjDQT9s/4qnw+26AD5bmP5vv8D95159+oqISVt/6v6mrpyuvd7dP8P93+vyTx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf8Aptm26AL8q/e+9wPm68+/UcVyfjXxXotx4W8SRQ+JdCmll0uWNEjuELSEpIAqgOfm59+o49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FCkubft/W4KnLlXu/h/h/u/1+WvdXO77X/ptm26AL8q/e+9wPm68+/UcVj/AGnd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUt14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqKyj4r0X/hKdclPiXQjFJpdrGri4Ta5D3RKqd/3huGev3hx6jkrrX+reoQpyt8Pbp/h/u/1+XWXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiluvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RWV418V6LceFvEkUPiXQppZdLljRI7hC0hKSAKoDn5uffqOPUnJcr1/r7wp05c0fd7dP8P8Ad/r8usurnd9r/wBNs23QBflX733uB83Xn36jii6ud32v/TbNt0AX5V+997gfN159+o4rIuvGGgn7Z/xVPh9t0AHy3Mfzff4H7zrz79RRdeMNBP2z/iqfD7boAPluY/m+/wAD95159+oq1Jd/608yY0pae726f4f7v9fkn2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcmfFei/wDCU65KfEuhGKTS7WNXFwm1yHuiVU7/ALw3DPX7w49dW68YaCftn/FU+H23QAfLcx/N9/gfvOvPv1FRCStv/V/Up05XXu9un+H+7/X5J47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiqPxT8Tt4b8DeI9VivYWnjshFC0MSsfNdjGhAZ8fKzqTnPHY9D5X8QPjm8tv4kstP0q0vNHkaTRzqK3yBmJRgZVhUsxT5mIfO0jbyCcVt/H/xZpmr+B30fSdc0K/k1q7tLIyw3a7IF8xpPMbazfKDGAT23g9sFr4n8v63MG06do7/AP7P93v/AF27vwB4kbxJ4C03VZNTtri4utNjFw5i8svMoZZVAyMEOGHAweMDGM3PtO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4rzb4AeKtGtfhNa2F1rmmWd3apPDNb3TiJwxmlcKNzDPyupyARzjqDXanxXov/CU65KfEuhGKTS7WNXFwm1yHuiVU7/vDcM9fvDj1JSV1r/X3mtGm3G9ui6f4f7p1l1c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jivMfGPxV1LxBq2qaJ8P8AUtDtoYQsVxr9/cxww5UOxSFHLGTOAu8Bh83QAq9SWvxYTxD4d8WaN4mbTNH8QJpUirFHcpNBeAwt/qZFcru3NjZljzxkhsE37rX9fmTRacou2l1rb0/unsV1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFZF14w0E/bP8AiqfD7boAPluY/m+/wP3nXn36isbxz8S9C8P+HtW1KPWtJ1OWO3RI7W0uIzJOzMyhV+c4xuyxwcLk4OMGlJd/608w5eRc0lZLy/w/3f6/LY+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiuL+IHxCm0f4ueFvD6amkdjf20n23Zbq6TGQOlugOWZW8wHkED5lJyM4oeDPipb6t4t8SxeKJNI8PXv2C2hiia+S4iuFUzMdkykRlv3yjaCT14+VsebfGTX7TVfjRZa79v06TS/D9zptq81vL5hmRmedpVVc5VPmRsE4O3u2AoabmdSW1vK+nZLyXY+jPHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFcn418V6LceFvEkUPiXQppZdLljRI7hC0hKSAKoDn5uffqOPWXxR8RfDWjaVqd/c+JNIuES3AEVpIsssxJYBEUOSWyevQZycAE0oyXNv2/rc3ceWCclZen+H+7/AF+XT3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFY/wBp3eL9e/02zbdpVovyr9795d8D5uvPv1HFeMXfxV8dzmbxHFH4Xj0l7dI30FtSha6MW0uZgdwbzPvJs+8CQDETzXb+Efid4e8T6nrmpR6va6erafb27W+oqtvKHWS6yoBkIJwynKlh8wHBBFDautf6+8mmn8LjZ6dPOP8Ad/r8vSLq53fa/wDTbNt0AX5V+997gfN159+o4rH8d3O7wh4o/wBNs23aVMvyr9793JwPm68+/UcUt14w0E/bP+Kp8PtugA+W5j+b7/A/edeffqK5f4p/EPQNO8Ha2Brmn3897aGxhgsCs0kjyLIoAAf5QMkljxj1JAJJ3i0n/X3lQg4tSktFbp/h/u/1+Xf3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFcRL4/E3xd1Dwil/pbW6aN5zuY2SRrndkQoS+G/dPv4B7+hFJ4U+K/h3xZpup3aanbaW0Y+ztb6mY4JnwCcqvmnj5sZ9QeOOfFU8QWN9+1BN4ga+tIdLaa5sxdSyxojNFZGIkfOcKzY2MThtwxzkC09TnkmuRpaXXT08j6K+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4rkz4r0X/AISnXJT4l0IxSaXaxq4uE2uQ90Sqnf8AeG4Z6/eHHrL4o+IvhrRtK1O/ufEmkXCJbgCK0kWWWYksAiKHJLZPXoM5OACainJW3/r7zonHltJrTTp/h/ul/wAd3O7wh4o/02zbdpUy/Kv3v3cnA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcV89638dbq9sdfj1fSFt9E1aymtdOlgKyXCEbo83EfmZj3FyemQBwJB81e2XHjHQJFumXxV4fdXtxgrdR/OPm4H7zrz79RQn7179v63FGN0o219P8P93+vy2Lq53fa/8ATbNt0AX5V+997gfN159+o4orHuPGOgSLdMvirw+6vbjBW6j+cfNwP3nXn36iitqcordndgIS5XZdunl6IXxDoWg63dT3OsWWgalcpbCNJbmzjlfALnapYkjkk/j09aFx4J8Hf6Vt0Dwmf3I27dMhGT83C+h6fpXTXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxUL+vw8zzowWmn4en905fRdO0rRfE/iGDRYtGsIJdMtGeOytkhWRt90OinG7GOee1Z3iH4X+BNXZjc6LoaGCImP7FGbUMTnIxE67jwOucZ4Ayc9D9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUQen9d/UpwWit26f4f7pxHxd8MeH/Enh7WL3WYNMu72y095be4ClJQyJKVUOrgkAsTtJKkkEjinad8NPA2j2t5b2WiaBLGyeYDcwfaXLEEYVpXZh0HAOOenXO747ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v/TbNt0AX5V+997gfN159+o4oT977v63BU1yp2/D/D/dC6ud32v/AE2zbdAF+Vfvfe4HzdeffqOK5TWdJ0bXfGOrtrVtoeptDpVqITc2iSlcyXWQm4naTgZx7eldXdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6jhHTbt0/w/wB3+vy4yb4K/DpftGzS7M7Ygy7by55PzcD9914Hr1HHra1XwT4W8NfD3xhp+i2mmRWl3p8ksqHdKZXRHKYZ5GOVIBHPBOQAeT6DdXO77X/ptm26AL8q/e+9wPm68+/UcVj+O7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4ok/df9fqKnTjzL3e3T0/unDP8ABfwjZ6vBe6Rf3OnxWckF4LK2ui0FxNEzlGYSM5LDJHB4DcAZJOp4u+HGka54lvPEFtr+oaPq81uEuLjSLwwtdrgKEbLNwBGnC4zwSCcV3t1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/ptm26AL8q/e+9wPm68+/UcVS/r8PMmNNaK34en93+vy8h034ReDbfxPqS35XWbmC1gvftV/cPJJPPJLcFi4DhXJ2ICCpBAGQSWLeqW0FlpljPZaW2l2lmkGEgtYVjj5LkhVVsA5Yk+7dPWj9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxUwen9d/UrkSasu3T/AA/3Tlvivp2na94I8QQ6s2n3kcNi1zDlSCssayMpQh8hgfTqGwRgkHmD8ING06S+Xw74t1/Q7KRRL9h0vUjHCzbdpADFmJO0ZJJ69hgV3Hju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOK2Lq53fa/wDTbNt0AX5V+997gfN159+o4oT977v63BU00nb8P8P9084t/hVokeq/b9c8Qaj4pe1t3W3i125F3EhfIJVTxuwo65HIOMgEczc/CdLbVNb0rwv431HS7H+z0P2Rn+0W7Qztdq9uIyw4GSVJLEF2P3jur226ud32v/TbNt0AX5V+997gfN159+o4rH+07vF+vf6bZtu0q0X5V+9+8u+B83Xn36jihvVf109RRpRlFpr+vd/u/wBflxviH4ZwX1j4dew8T/2frvhvTorS01G1hT98qrtKuhYlgQrDbux+8bIIJBy/GHgfXLjRtfv/ABD8T9Wv3g01zFDYKlhDKFWRikkaMVfOQOgODjnjHr11c7vtf+m2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jinJ+6/6/UVOjFyjddv08v6/LH8GeAfDHgaO9/wCEeWzW6ls1hlupGaSWYDOQCXIUkgEhQATt+XgUvxA8FaV4u1CDUZ9Vk0/VrCLEGoaXL5E5Qhw0W7JyDuPqeeMAtu6+6ud32v8A02zbdAF+Vfvfe4HzdeffqOKLq53fa/8ATbNt0AX5V+997gfN159+o4ql/X4eYRgtFb8PT+6eR2vhLxbY67rFlpvxTmMcdjCyy3enw3U0sbS3JWJndssV+b5u+8DACgV65dXO77X/AKbZtugC/Kv3vvcD5uvPv1HFY/2nd4v17/TbNt2lWi/Kv3v3l3wPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFTB3X9d/UapKLVl27/AN3y/r8sfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFbF1c7vtf+m2bboAvyr9773A+brz79RxWL4+nL+EfEpGoWv8AyC5gQij95+6l+UfMeec8e347V1c7vtf+m2bboAvyr9773A+brz79RxST977v63KUfdWn4f4f7v8AX5F1c7vtf+m2bboAvyr9773A+brz79RxWP8Aad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVj/ad3i/Xv8ATbNt2lWi/Kv3v3l3wPm68+/UcUN6x/rp6hCOm3bp/h/u/wBflsXVzu+1/wCm2bboAvyr9773A+brz79RxWP47ud3hDxR/ptm27Spl+Vfvfu5OB83Xn36jiti6ud32v8A02zbdAF+Vfvfe4HzdeffqOKx/Hdzu8IeKP8ATbNt2lTL8q/e/dycD5uvPv1HFE37r/r9QpR96Onbp/h/u/1+WxdXO77X/ptm26AL8q/e+9wPm68+/UcUXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFF1c7vtf+m2bboAvyr9773A+brz79RxRdXO77X/AKbZtugC/Kv3vvcD5uvPv1HFWn/X3eZMY7adun+H+7/X5eT33w30+bx34on0zxZrWjreQw6hPFpV95KTzSPOHBBJJ5TOMnBc4wMAWP8AhS/g+SS+uNcvLrxFfyKJPtupX0jTNhdoQFHUHAUdQTyO2BXcfad3i/Xv9Ns23aVaL8q/e/eXfA+brz79RxWxdXO77X/ptm26AL8q/e+9wPm68+/UcVEHdf1/mDpK607dP8P93+vy5LxTo+kad8M9d0Wyj0pdKt9JkWG2EQZMqruuMscuGw245O4huvJpW3wv8DadrsusWOl6Wl/Fm4iKtIY1kO77kZkKKRwQAuFO0gDArovHdzu8IeKP9Ns23aVMvyr9793JwPm68+/UcVsXVzu+1/6bZtugC/Kv3vvcD5uvPv1HFCfvfd/W41BWTt+H+H+6fNOkaRe+Ivin4z8Ea1qAs9BGo3XiC5t7dh/xMNzxmKNnDcIQ6Pgcg5z8wBXuR8Hvh+fEeq2o02zaCCwt5olW7uP9Yz3AbB87OcRp1yOnHXPoVlolnpviPxTrVvqUcl1rcVubhWxszFG0arGAcg465LckdKf9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFDeq/r9SKNHR8yv8vOP93sWdLsdP0LSDpejvp9tp9vaiKKGFeMfOcDLkliSSScklsnnrzfxf8P6L4m8LatNra6feTafYy3FpINyOkgRzhWVweuCVOQcLkHArs7q53fa/9Ns23QBflX733uB83Xn36jisfx3c7vCHij/TbNt2lTL8q/e/dycD5uvPv1HFOT91/wBfqaU4JtJrt0/w/wB3+vy4i/8Agp4FFveJpi/2bcGAqtzZXswkwwYOi75GU7lyjAg5VyMDrWhpnwo8B6Jqf9oabpunrd2qeZA7TTSgPhhlVeVhuHBBIODgjBGa7+6ud32v/TbNt0AX5V+997gfN159+o4ournd9r/02zbdAF+Vfvfe4HzdeffqOKpf1+HmRGmrp27dPT+6cV4p8N6B4t8T63D4hg0rUAulWYjdo8SL+9uWxHIH3KcgZweRgEY68t8S/AujeHfg94x0/wAHWtjCJ4oLqZUlLNIIpQ7fPJIT8qKx25PU4GTz6N9p3eL9e/02zbdpVovyr9795d8D5uvPv1HFXPEUEWsaRrOnXN/b+Re2L20jRABirq6kLliA2G9D1HHrEHp/X+YVKSasl0XTyj/dPCNM8N2PxD8Aa34/8bXSahrd3Z3E1pCzvFHYrEZlSKJVkGRld3zbs7hkE7mf0TTPhR4D0TU/7Q03TdPW7tU8yB2mmlAfDDKq8rDcOCCQcHBGCM1sa5aQaL8M9W0m01CCW2stBa0iZwC8ixwuoGQ2N2Bzgd+grp7q53fa/wDTbNt0AX5V+997gfN159+o4pp+9939bhCkoxjp+H+H+6F1c7vtf+m2bboAvyr9773A+brz79RxXm3i3wTYeI/iJqmpxeILzR76LSrdXm0acWz3YZ5gVkPJY4ijH0CjsK9Jurnd9r/02zbdAF+Vfvfe4HzdeffqOKx/tO7xfr3+m2bbtKtF+VfvfvLvgfN159+o4pN6r+unqVGCa1Xbp/h/unE3nw0vY47hLH4o+KtsiIJzPfCYyxBtxjjOQY3yo+cZ4YgghiDS8Q/DHSbLTdY1bVPEuq+JLqw0u5NmNZu/tKRO0bfNGOMONox1AJBxkKR63dXO77X/AKbZtugC/Kv3vvcD5uvPv1HFY/ju53eEPFH+m2bbtKmX5V+9+7k4HzdeffqOKJv3X/X6hSppTi7dv0/u/wBflzXjL4a+H/EOv3OvLqVxpuvFVkOoaZdNFLJiNo/LGWZQCoUHAyePU54L4taDafD3wNpU+kzXGsC18R2+r3s80pkluJMS5eR+QMnYucdWXOSSW96urnd9r/02zbdAF+Vfvfe4HzdeffqOK5z4l6EvjLwjrOhtrFpbC7ihPnJFv5jl8wALvGT8uOv8Q/G0/wCvu8zNwfL7q19PT+7/AF+XmPhnw3rXjK6vdd8R+O9Wsr3UdNtNQW20W7NvDHFKZ9lvg5ztVQfrI2dxyzddp3wx0my12PVtU8S6p4jurGFjZjWbv7SkTt/Eg4w42jHUAkHGQpHTWhhtfEusW1pcafFbx6PZQxRQxhUCq90AiANgYHGB7cVu3Vzu+1/6bZtugC/Kv3vvcD5uvPv1HFTB3X9d/UtUlG2nb/23+7/X5Y3j6cSeDvFKteWbq+kzqQF+/wDu5PlHzdeffqOK4hfhJp+nx3Nvo/jnxRp1gqs8VlZapshQMzt5aDk4BJ6kn5uck5PceO7nd4Q8Uf6bZtu0qZflX737uTgfN159+o4rYurnd9r/ANNs23QBflX733uB83Xn36jikn733f1uPkTitPw/w/3f6/KLMNrazW1pcafFbx2qwxRQxhUCqGARAGwMDjA9uKKlurnd9r/02zbdAF+Vfvfe4HzdeffqOKK6KR3YFWT+X5eiM+8tfE/+nbtX0U/6MN2NKlGR8/A/0njvReWvif8A07dq+in/AEYbsaVKMj5+B/pPHeiio5EeVGtLTbp0X93yMp7bxH/wlOvD+1dI80aVal2/syTay77rAA+0cEfNk5OcjgY51by18T/6du1fRT/ow3Y0qUZHz8D/AEnjvRRUQirf13K9rK626dF/d8jK8cW3iNfC3ic3Gq6RJENKlMix6ZIjMuyTIBNwcHryQfp66t5a+J/9O3avop/0YbsaVKMj5+B/pPHeiihRXN9wRqy5Y7fcv7vkF5a+J/8ATt2r6Kf9GG7GlSjI+fgf6Tx3rKe28R/8JTrw/tXSPNGlWpdv7Mk2su+6wAPtHBHzZOTnI4GOSihxV1/XQKdWVunTov7vkat5a+J/9O3avop/0YbsaVKMj5+B/pPHesrxxbeI18LeJzcarpEkQ0qUyLHpkiMy7JMgE3BwevJB+nqUUTiuVhSqy5o7dOi/u+Rq3lr4n/07dq+in/RhuxpUoyPn4H+k8d6Ly18T/wCnbtX0U/6MN2NKlGR8/A/0njvRRV8iJjWlpt06L+75GU9t4j/4SnXh/aukeaNKtS7f2ZJtZd91gAfaOCPmycnORwMc6t5a+J/9O3avop/0YbsaVKMj5+B/pPHeiiohFW/ruV7WV1t06L+75GV44tvEa+FvE5uNV0iSIaVKZFj0yRGZdkmQCbg4PXkg/T11by18T/6du1fRT/ow3Y0qUZHz8D/SeO9FFCiub7gjVlyx2+5f3fILy18T/wCnbtX0U/6MN2NKlGR8/A/0njvWU9t4j/4SnXh/aukeaNKtS7f2ZJtZd91gAfaOCPmycnORwMclFDirr+ugU6srdOnRf3fI1by18T/6du1fRT/ow3Y0qUZHz8D/AEnjvWV44tvEa+FvE5uNV0iSIaVKZFj0yRGZdkmQCbg4PXkg/T1KKJxXKwpVZc0dunRf3fI1by18T/6du1fRT/ow3Y0qUZHz8D/SeO9F5a+J/wDTt2r6Kf8ARhuxpUoyPn4H+k8d6KKvkRMa0tNunRf3fIyntvEf/CU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjnVvLXxP/p27V9FP+jDdjSpRkfPwP9J470UVEIq39dyvayutunRf3fIyvHFt4jXwt4nNxqukSRDSpTIsemSIzLskyATcHB68kH6eureWvif/AE7dq+in/RhuxpUoyPn4H+k8d6KKFFc33BGrLljt9y/u+QXlr4n/ANO3avop/wBGG7GlSjI+fgf6Tx3rKe28R/8ACU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjkoocVdf10CnVlbp06L+75GreWvif/Tt2r6Kf9GG7GlSjI+fgf6Tx3rK8cW3iNfC3ic3Gq6RJENKlMix6ZIjMuyTIBNwcHryQfp6lFE4rlYUqsuaO3Tov7vkat5a+J/8ATt2r6Kf9GG7GlSjI+fgf6Tx3ovLXxP8A6du1fRT/AKMN2NKlGR8/A/0njvRRV8iJjWlpt06L+75GU9t4j/4SnXh/aukeaNKtS7f2ZJtZd91gAfaOCPmycnORwMc6t5a+J/8ATt2r6Kf9GG7GlSjI+fgf6Tx3ooqIRVv67le1ldbdOi/u+RleOLbxGvhbxObjVdIkiGlSmRY9MkRmXZJkAm4OD15IP09dW8tfE/8Ap27V9FP+jDdjSpRkfPwP9J470UUKK5vuCNWXLHb7l/d8gvLXxP8A6du1fRT/AKMN2NKlGR8/A/0njvWU9t4j/wCEp14f2rpHmjSrUu39mSbWXfdYAH2jgj5snJzkcDHJRQ4q6/roFOrK3Tp0X93yNW8tfE/+nbtX0U/6MN2NKlGR8/A/0njvWV44tvEa+FvE5uNV0iSIaVKZFj0yRGZdkmQCbg4PXkg/T1KKJxXKwpVZc0dunRf3fI1by18T/wCnbtX0U/6MN2NKlGR8/A/0njvReWvif/Tt2r6Kf9GG7GlSjI+fgf6Tx3ooq+RExrS026dF/d8jKe28R/8ACU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjnVvLXxP/AKdu1fRT/ow3Y0qUZHz8D/SeO9FFRCKt/Xcr2srrbp0X93yMrxxbeI18LeJzcarpEkQ0qUyLHpkiMy7JMgE3BwevJB+nrq3lr4n/ANO3avop/wBGG7GlSjI+fgf6Tx3oooUVzfcEasuWO33L+75BeWvif/Tt2r6Kf9GG7GlSjI+fgf6Tx3rKe28R/wDCU68P7V0jzRpVqXb+zJNrLvusAD7RwR82Tk5yOBjkoocVdf10CnVlbp06L+75GreWvif/AE7dq+in/RhuxpUoyPn4H+k8d6yvHFt4jXwt4nNxqukSRDSpTIsemSIzLskyATcHB68kH6epRROK5WFKrLmjt06L+75GreWvif8A07dq+in/AEYbsaVKMj5+B/pPHei8tfE/+nbtX0U/6MN2NKlGR8/A/wBJ470UVfIiY1pabdOi/u+RlPbeI/8AhKdeH9q6R5o0q1Lt/Zkm1l33WAB9o4I+bJyc5HAxzq3lr4n/ANO3avop/wBGG7GlSjI+fgf6Tx3ooqIRVv67le1ldbdOi/u+RleOLbxGvhbxObjVdIkiGlSmRY9MkRmXZJkAm4OD15IP09dW8tfE/wDp27V9FP8Aow3Y0qUZHz8D/SeO9FFCiub7gjVlyx2+5f3fILy18T/6du1fRT/ow3Y0qUZHz8D/AEnjvRRRW0IL+mz0MtqNxlt06Lsf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22407=[""].join("\n");
var outline_f21_56_22407=null;
var title_f21_56_22408="Clinical manifestations and diagnosis of chronic pulmonary aspergillosis";
var content_f21_56_22408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/56/22408/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/56/22408/contributors\">",
"     David W Denning, MBBS, FRCP, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/56/22408/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/56/22408/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/56/22408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/56/22408/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/56/22408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary aspergillosis includes several disease manifestations, including aspergilloma, chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, and chronic necrotizing aspergillosis (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    below). A duration of disease longer than three months distinguishes chronic pulmonary aspergillosis from invasive pulmonary aspergillosis.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, and diagnosis of chronic pulmonary aspergillosis will be reviewed here. The treatment of chronic pulmonary aspergillosis, as well as allergic bronchopulmonary aspergillosis (ABPA) and invasive aspergillosis, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link\">",
"     \"Treatment of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pulmonary aspergillosis describes several patterns of disease. However, the terminology that has been developed can be difficult to apply to a spectrum of disease entities that have considerable overlap and variation in severity. The following terminology will be used to describe the spectrum of disease; each entity is characterized by specific radiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspergilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aspergilloma is a fungus ball composed of Aspergillus hyphae, fibrin, mucus, and cellular debris found within a pulmonary cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/2\">",
"     2",
"    </a>",
"    ]. Aspergillomas arise in preexisting pulmonary cavities that have become colonized with Aspergillus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the aspergilloma is single, the cavity stable over months, and the patient has few symptoms (ie, a mild cough only) and little evidence of systemic inflammation, a simple aspergilloma may be diagnosed. We will use the term \"simple aspergilloma\" to distinguish this entity from the more complex forms of chronic pulmonary aspergillosis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic cavitary pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term, \"chronic cavitary pulmonary aspergillosis,\" describes a pattern of disease in immunocompetent patients in whom there is formation and expansion of one or more pulmonary cavities over months (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54038 \" href=\"UTD.htm?31/11/31924\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65409 \" href=\"UTD.htm?39/30/40420\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77208 \" href=\"UTD.htm?24/12/24773\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56179 \" href=\"UTD.htm?15/42/16033\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]. This term is preferred over the older term, \"complex aspergilloma,\" because more than 50 percent of such patients don't have an aspergilloma visible radiographically. Almost all patients with chronic cavitary pulmonary aspergillosis have Aspergillus IgG antibodies (precipitins) in the blood. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Radiographic features'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Laboratory findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic fibrosing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic fibrosing pulmonary aspergillosis is a late-stage manifestation of chronic cavitary pulmonary aspergillosis in which progression to marked and extensive fibrosis has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic necrotizing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term, \"chronic necrotizing pulmonary aspergillosis,\" is best reserved for patients with some degree of immunocompromise who have a shorter duration of illness compared with patients with chronic cavitary pulmonary aspergillosis (eg, weeks rather than months) and in whom hyphal invasion of tissue is observed histologically, or can be inferred based upon radiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]. Such patients usually have a single thin-walled cavity or area of cavitating",
"    <span class=\"nowrap\">",
"     pneumonia/consolidation",
"    </span>",
"    and may have detectable Aspergillus antigen (galactomannan) or Aspergillus IgG antibodies (precipitins) in blood. We favor the term \"subacute invasive pulmonary aspergillosis\" to describe this process since it is thought to represent a slowly progressive form of invasive aspergillosis; however, we will use the term \"chronic necrotizing pulmonary aspergillosis,\" since it is more widely recognized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of chronic pulmonary aspergillosis remains incompletely understood. Although patients with chronic pulmonary aspergillosis are generally immunocompetent, all patients with chronic pulmonary aspergillosis have either prior pulmonary damage or disease. Aspergillomas almost always arise in preexisting cavities in the lungs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mycology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all cases of chronic pulmonary aspergillosis are caused by A. fumigatus, although patients have been described with A. niger or A. flavus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Occasionally A. fumigatus isolates may be atypical, growing slowly with poor sporulation, delaying identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Underlying diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common underlying diseases that predispose patients to chronic pulmonary aspergillosis include pulmonary tuberculosis, allergic bronchopulmonary aspergillosis, lung cancer (following successful treatment), prior pneumothorax with associated bulla formation, chronic obstructive pulmonary disease, and fibrocavitary sarcoidosis (",
"    <a class=\"graphic graphic_table graphicRef67910 \" href=\"UTD.htm?30/40/31371\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Celiac disease may be more slightly common in those with chronic pulmonary aspergillosis. Chronic pulmonary aspergillosis can also evolve from invasive pulmonary aspergillosis that has not completely resolved.",
"   </p>",
"   <p>",
"    Patients with classical pulmonary tuberculosis who are left with cavities of &ge;2 cm have an approximately 20 percent chance of subsequently developing aspergillomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In a study that used modeling to estimate the global burden of chronic pulmonary aspergillosis as a sequela of pulmonary tuberculosis, the prevalence of chronic pulmonary aspergillosis varied widely, with a lower prevalence in developed countries than in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;The estimated country prevalence of chronic pulmonary aspergillosis ranged from &lt;1 case per 100,000 population in large western European countries and the United States to 42.9 per 100,000 population in both the Democratic Republic of the Congo and Nigeria. China and India had intermediate prevalence rates of 16.2 and 23.1 per 100,000 population respectively, reflecting the variable frequency of pulmonary tuberculosis. Overall, an estimated 1.2 million people have chronic pulmonary aspergillosis following pulmonary tuberculosis. Patients with a history of pulmonary infection caused by nontuberculous mycobacteria, such as M. xenopi, M. malmoense, or M. avium complex, may have a higher rate of subsequent chronic pulmonary aspergillosis when compared with patients with a history of pulmonary tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike the other forms of chronic pulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis often occurs in immunocompromised patients such as those with diabetes mellitus, alcoholism, and individuals receiving glucocorticoids (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Role of glucocorticoids'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, invasive aspergillosis occurs most commonly in profoundly immunocompromised patients, such as neutropenic patients with hematologic malignancies, and transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with chronic pulmonary aspergillosis appear to have genetic defects in one of more innate immune functions, such as toll-like receptor 4, or surfactant A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The interrelationship of these defects with disease expression is complex. For example, in one study, higher MBL levels were linked with increased breathlessness in CPA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/14\">",
"     14",
"    </a>",
"    ], whereas prior small studies had suggested an association with low MBL levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/15\">",
"     15",
"    </a>",
"    ]. Cytokine production profiles are most consistent with a Th2 profile in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic pulmonary aspergillosis are frequently deficient in mannose-binding lectin and have poor antibody responses to polysaccharide antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Some are unable to produce interferon gamma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=see_link&amp;anchor=H22#H22\">",
"     \"Mannose-binding lectin deficiency\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of chronic pulmonary aspergillosis\", section on 'Clinical failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids given without antifungal therapy in patients with chronic pulmonary aspergillosis may accelerate lung destruction, especially in patients with sarcoidosis or rheumatoid arthritis. Presumably, cavities expand because the Aspergillus growing on the interior surface of the cavity secretes proteins (eg, proteases, phospholipases, catalases, and others) or secondary metabolic products (eg, gliotoxin), which lead to ongoing inflammation and progressive localized lung tissue damage. It is not clear why new cavities form without tissue invasion being demonstrable, why fungal balls are present in some cavities and not others, and why abnormal bronchial arterial vasculature forms, resulting in hemoptysis. Glucocorticoids may be helpful in resolving inflammation in those receiving adequate antifungal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillomas in the lung are rounded conglomerates of hyphae, mucus, and cellular debris that may be loosely attached to the wall of a pulmonary cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/2\">",
"     2",
"    </a>",
"    ]. On histologic section, a pulmonary aspergilloma has a lamellar appearance. Oxalate crystals may be visible in tissue, especially in patients with A. niger infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic cavitary pulmonary aspergillosis is characterized pathologically by chronic inflammation with localized fibrosis, usually without granulomas, necrosis, or eosinophilic infiltrates. Cavity walls may be composed of three layers: necrotic, granulation, and fibrotic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/17\">",
"     17",
"    </a>",
"    ]. Hyphae do not invade tissue, unless the patient becomes immunocompromised and localized invasive disease supervenes, as occurs with chronic necrotizing pulmonary aspergillosis. The distinction between chronic cavitary pulmonary aspergillosis and chronic necrotizing pulmonary aspergillosis is particularly difficult in patients with rheumatoid arthritis receiving modest doses of immunosuppressants.",
"   </p>",
"   <p>",
"    Chronic fibrosing pulmonary aspergillosis is characterized by extensive fibrosis and some chronic inflammation distant from a cavity and involving large sections of lung [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic pulmonary aspergillosis vary in age from 20 to over 80 years old, but are typically in their middle years. In a series of 18 patients with chronic pulmonary aspergillosis, the median age was 59 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]. The cavitary and fibrosing forms of chronic pulmonary aspergillosis usually progress slowly over months or years, but the necrotizing form usually progresses more rapidly over weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic pulmonary aspergillosis present most commonly with weight loss, chronic productive cough, hemoptysis of variable severity, fatigue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shortness of breath [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Fever and night sweats occur occasionally. The systemic symptoms of chronic cavitary pulmonary aspergillosis are an important point of distinction from a simple aspergilloma, in which these do not occur.",
"   </p>",
"   <p>",
"    In a series of 18 patients with chronic pulmonary aspergillosis, the various signs and symptoms were present with the following frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss &mdash; 17 patients (94 percent)",
"     </li>",
"     <li>",
"      Cough &mdash; 14 patients (78 percent)",
"     </li>",
"     <li>",
"      Shortness of breath &mdash; 9 patients (50 percent)",
"     </li>",
"     <li>",
"      Hemoptysis &mdash; 10 patients (58 percent)",
"     </li>",
"     <li>",
"      Moderate to severe",
"      <span class=\"nowrap\">",
"       fatigue/malaise",
"      </span>",
"      &mdash; 5 patients (28 percent)",
"     </li>",
"     <li>",
"      Chest pain &mdash; 3 patients (17 percent)",
"     </li>",
"     <li>",
"      Substantial sputum production &mdash; 2 patients (11 percent)",
"     </li>",
"     <li>",
"      Fever &mdash; 2 patients (11 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic examination usually reveals one or more cavities, typically within the upper lobes, which may or may not contain fungus balls (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54038 \" href=\"UTD.htm?31/11/31924\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65409 \" href=\"UTD.htm?39/30/40420\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77208 \" href=\"UTD.htm?24/12/24773\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56179 \" href=\"UTD.htm?15/42/16033\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A simple aspergilloma is a fungus ball in a single pulmonary cavity with limited surrounding inflammation, pleural thickening, or fibrosis. The radiographic appearance remains stable over several months, unlike in chronic cavitary pulmonary aspergillosis, in which cavities may expand or coalesce.",
"   </p>",
"   <p>",
"    Chronic cavitary pulmonary aspergillosis usually begins as ill-defined regions of consolidation that progress to form clearly-defined cavities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]. Cavities may contain fungus balls, debris, or fluid. There are often multiple cavities of different sizes. It is most common for the cavities to be thin-walled and to lack associated pleural thickening, although both thick cavity walls and pleural thickening occur in some cases. If pericavitary infiltrates and pleural thickening adjacent to cavities are present, they generally improve very slowly with appropriate therapy, leaving residual thin-walled empty cavities. New cavity formation or expansion of one or more existing cavities over time is highly characteristic, and typically occurs over months in the absence of treatment.",
"   </p>",
"   <p>",
"    Single or multiple nodules are also seen in chronic pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/19\">",
"     19",
"    </a>",
"    ]. These may or may not cavitate, forming a small air crescent, and may develop into larger cavities over time. Such nodules have been noted to be moderately or strongly positive on positron emission tomography scanning, mimicking carcinoma of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Chronic fibrosing pulmonary aspergillosis is characterized by the same radiographic findings that occur with chronic cavitary pulmonary aspergillosis in combination with significant fibrosis.",
"   </p>",
"   <p>",
"    In contrast to chronic cavitary pulmonary aspergillosis, thin-walled cavities or consolidation with cavitation associated with chronic necrotizing pulmonary aspergillosis usually worsen over weeks to a few months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the diagnosis of chronic pulmonary aspergillosis can be inferred from a single chest radiograph, detailed and sequentially acquired radiographic data may be required to observe both the typical radiographic features and the very slow progression (over months or years) that is characteristic of the cavitary and fibrotic forms of this disease. CT scans may be useful to define the precise pattern and extent of involvement.",
"   </p>",
"   <p>",
"    Serial imaging is useful not only for following the progression of disease prior to starting therapy, but also for evaluating the response to therapy. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Monitoring during therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal test for chronic pulmonary aspergillosis is a positive Aspergillus antibody test (precipitins) from the serum. However, standardization of this testing is not well established for this indication. Most patients with chronic cavitary pulmonary aspergillosis, including those with simple aspergillomas, have positive Aspergillus IgG antibodies (precipitins) in the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 50 percent of patients with chronic pulmonary aspergillosis have positive Aspergillus IgE tests, and some have slightly elevated total serum IgE levels without having allergic bronchopulmonary aspergillosis (ABPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with ABPA as their underlying diagnosis usually have very high total IgE and Aspergillus IgE results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few patients (10 to 40 percent) with chronic pulmonary aspergillosis have positive cultures of A. fumigatus (or rarely other Aspergillus species) in their sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/18\">",
"     18",
"    </a>",
"    ]. A higher proportion has a positive Aspergillus polymerase chain reaction (PCR) from the sputum or bronchoalveolar lavage (BAL) fluid. Among 42 patients with chronic pulmonary aspergillosis, 71 percent had a positive PCR from the sputum but only 17 percent had a positive culture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/24\">",
"     24",
"    </a>",
"    ]. However, 4 of 11 normal volunteers had a positive PCR from BAL, so false positive results can occur and are likely due to transient colonization or contamination of samples.",
"   </p>",
"   <p>",
"    Elevated galactomannan and beta-D-glucan levels have been reported in some patients with chronic pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/25\">",
"     25",
"    </a>",
"    ]. In a retrospective cohort study that included 48 patients with pulmonary aspergilloma, the galactomannan assay had a sensitivity of 38 percent for serum and 92 percent for BAL fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/26\">",
"     26",
"    </a>",
"    ]. Galactomannan detection from serum was higher in patients with hemoptysis compared with those without hemoptysis (52 versus 9 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486430#H1064486430\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Galactomannan antigen detection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated inflammatory markers, such as C-reactive protein (CRP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythrocyte sedimentation rate (ESR), are very common in patients with chronic pulmonary aspergillosis but are not specific [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have significant reduction in pulmonary function, with the character and degree of abnormalities reflecting their underlying pulmonary disease. Chronic fibrosing pulmonary aspergillosis leads to major reductions in vital and diffusing capacity, often with abnormally low oxygen saturations. Hypoxic respiratory failure with either hypocapnia or hypercapnia may occur, typically during an acute bacterial infection.",
"   </p>",
"   <p>",
"    A flight assessment is useful to determine the need for supplemental oxygen for air travel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once chronic pulmonary aspergillosis is considered, usually on the basis of general symptoms of fatigue and weight loss with one or more cavities in one or both lung apices with negative tests for tuberculosis, the diagnosis is established by a positive Aspergillus IgG serology (precipitins). Some patients have a positive culture of Aspergillus spp from the lungs, but this alone is insufficient to make the diagnosis of chronic pulmonary aspergillosis if Aspergillus IgG antibodies are negative or pending.",
"   </p>",
"   <p>",
"    In patients with negative fungal cultures, bronchoscopy should be considered to collect samples for fungal and mycobacterial stains and cultures and to exclude malignancy. Atypical mycobacterial disease can precede, occur concurrently, or follow chronic pulmonary aspergillosis. Concurrent bacterial infection (often an exacerbation of bronchiectasis) is common, and occasionally occurs in a cavity, resulting in a fluid level. Ultrasound- or CT-guided aspiration may be required to document the pathogen, such as methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Aspergilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for the diagnosis of aspergilloma are radiologic evidence of a rounded mass in a pulmonary cavity combined with microbiologic evidence of Aspergillus as the causative agent, usually a positive culture from sputum or detectable Aspergillus precipitins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/27\">",
"     27",
"    </a>",
"    ]. Since aspergillomas may occur in the context of chronic cavitary pulmonary aspergillosis, the distinction between a simple aspergilloma and chronic cavitary pulmonary aspergillosis relies on symptomatology, evidence of inflammation, the radiologic appearance, and change over time. If the aspergilloma is single, the cavity stable over months, and the patient has few symptoms (ie, a mild cough only) and little evidence of systemic inflammation, a simple aspergilloma may be diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic cavitary pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific criteria we suggest for the diagnosis of chronic cavitary pulmonary aspergillosis are [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One large empty cavity or two or more cavities on chest imaging with or without a fungal ball (aspergilloma) in one or more of the cavities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AND",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least one of the following symptoms for at least three months: fever, weight loss, fatigue, cough, sputum production, hemoptysis, or shortness of breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AND",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive Aspergillus serology (precipitins)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      culture of Aspergillus spp from the lungs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chronic fibrosing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for the diagnosis of chronic fibrosing pulmonary aspergillosis are similar to those for chronic cavitary pulmonary aspergillosis. In addition, substantial areas of fibrosis (determined by biopsy or inferred from CT scanning of the thorax) in immediate proximity to an area of chronic cavitary pulmonary aspergillosis are seen, and there is major impairment of respiratory function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chronic necrotizing pulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for the diagnosis of chronic necrotizing pulmonary aspergillosis are the same as those for invasive pulmonary aspergillosis, and include some evidence of immunosuppression in most cases, and progression over weeks rather than months; patients may have detectable Aspergillus antigen (galactomannan) or Aspergillus antibody (precipitins) in the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22408/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Confirmation requires a biopsy of the pulmonary lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486416#H1064486416\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Diagnostic modalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus serology (precipitins) and inflammatory markers (C-reactive protein and erythrocyte sedimentation rate) should be repeated approximately every three months during therapy, and chest radiographs every 6 to 12 months, depending on clinical status (ie, earlier if deterioration occurs). CT scans of the thorax are indicated if there is a major change in clinical status not attributable to a concurrent bacterial infection, new chest radiographic findings despite apparent clinical improvement, and for follow-up evaluation every 12 to 14 months, until clinical stability on therapy is achieved. The expected changes in laboratory and radiographic findings following the initiation of therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of chronic pulmonary aspergillosis\", section on 'Assessing treatment response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Apparent exacerbations must be distinguished from concurrent bacterial respiratory infections, exacerbations of asthma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic bronchopulmonary aspergillosis, recurrence or development of tuberculosis or nontuberculous mycobacterial infection, and tumor development or recurrence in those at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of chronic pulmonary aspergillosis\", section on 'Clinical failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/6/31842?source=see_link\">",
"       \"Patient information: Chronic pulmonary aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pulmonary aspergillosis includes several disease manifestations, including aspergilloma, chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, and chronic necrotizing aspergillosis. A duration of disease longer than three months distinguishes chronic pulmonary aspergillosis from invasive pulmonary aspergillosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Almost all cases of chronic pulmonary aspergillosis are caused by A. fumigatus, although patients have been described with A. niger or A. flavus infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mycology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with chronic pulmonary aspergillosis have either prior pulmonary damage or disease. The most common underlying diseases that predispose patients to chronic pulmonary aspergillosis include pulmonary tuberculosis, allergic bronchopulmonary aspergillosis, lung cancer (following successful treatment), prior pneumothorax with associated bulla formation, chronic obstructive pulmonary disease, and fibrocavitary sarcoidosis (",
"      <a class=\"graphic graphic_table graphicRef67910 \" href=\"UTD.htm?30/40/31371\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Underlying diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with chronic pulmonary aspergillosis have genetic defects in one of more innate immune functions, such as mannose-binding lectin, toll-like receptor 4, or surfactant A2. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genetic defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic cavitary pulmonary aspergillosis present most commonly with weight loss, chronic productive cough, hemoptysis of variable severity, fatigue,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shortness of breath. Fever and night sweats occur occasionally. The systemic symptoms of chronic cavitary pulmonary aspergillosis are an important point of distinction from a simple aspergilloma, in which these do not occur. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic examination usually reveals one or more cavities, typically within the upper lobes, which may or may not contain fungus balls. New cavity formation or expansion of one or more existing cavities over time is highly characteristic of chronic cavitary pulmonary aspergillosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardinal test for chronic pulmonary aspergillosis is a positive Aspergillus antibody test (precipitins) from the serum. However, standardization of this testing is not well established for this indication. Few patients (10 to 40 percent) with chronic pulmonary aspergillosis have positive cultures of A. fumigatus (or rarely other Aspergillus species) in their sputum, but Aspergillus polymerase chain reaction from the sputum is usually positive. More than 50 percent of patients have positive Aspergillus IgE tests, and some have slightly elevated total serum IgE levels without having allergic bronchopulmonary aspergillosis (ABPA). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated inflammatory markers, such as C-reactive protein",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erythrocyte sedimentation rate, are very common in patients with chronic pulmonary aspergillosis but are not specific. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once chronic pulmonary aspergillosis is considered, usually on the basis of general symptoms of fatigue and weight loss with one or more cavities in one or both lung apices with negative tests for tuberculosis; the diagnosis is established by a positive Aspergillus IgG serology (precipitins). Some patients have a positive culture of Aspergillus spp from the lungs, but this alone is insufficient to make the diagnosis of chronic pulmonary aspergillosis if Aspergillus IgG antibodies are negative or pending. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspergillus serology (precipitins) and inflammatory markers (C-reactive protein and erythrocyte sedimentation rate) should be repeated approximately every three months during therapy, and chest radiographs every 6 to 12 months, depending on clinical status (ie, earlier if deterioration occurs). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Monitoring during therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/1\">",
"      Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 Suppl 3:S265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/2\">",
"      Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. Curr Opin Investig Drugs 2001; 2:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/3\">",
"      Severo LC, Geyer GR, Porto Nda S, et al. Pulmonary Aspergillus niger intracavitary colonization. Report of 23 cases and a review of the literature. Rev Iberoam Micol 1997; 14:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/4\">",
"      Pasqualotto AC, Denning DW. An aspergilloma caused by Aspergillus flavus. Med Mycol 2008; 46:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/5\">",
"      Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/6\">",
"      Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 2011; 189:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/7\">",
"      Sonnenberg P, Murray J, Glynn JR, et al. Risk factors for pulmonary disease due to culture-positive M. tuberculosis or nontuberculous mycobacteria in South African gold miners. Eur Respir J 2000; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/8\">",
"      Lee JJ, Chong PY, Lin CB, et al. High resolution chest CT in patients with pulmonary tuberculosis: characteristic findings before and after antituberculous therapy. Eur J Radiol 2008; 67:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/9\">",
"      Aspergilloma and residual tuberculous cavities--the results of a resurvey. Tubercle 1970; 51:227.",
"     </a>",
"    </li>",
"    <li>",
"     Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. file://www.who.int/bulletin/volumes/89/12/11-089441.pdf (Accessed on January 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/11\">",
"      Smith N, Denning DW. Underlying pulmonary disease frequency in patients with chronic pulmonary aspergillosis. Eur Respir J 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/12\">",
"      Vaid M, Kaur S, Sambatakou H, et al. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007; 45:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/13\">",
"      Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008; 197:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/14\">",
"      Harrison E, Singh A, Morris J, et al. Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet 2012; 39:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/15\">",
"      Crosdale DJ, Poulton KV, Ollier WE, et al. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001; 184:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/16\">",
"      Sambatakou H, Pravica V, Hutchinson IV, Denning DW. Cytokine profiling of pulmonary aspergillosis. Int J Immunogenet 2006; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/17\">",
"      Sugino K, Hasegawa C, Sano G, et al. Pathophysiological study of chronic necrotizing pulmonary aspergillosis. Jpn J Infect Dis 2008; 61:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/18\">",
"      Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/19\">",
"      Baxter CG, Bishop P, Low SE, et al. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax 2011; 66:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/20\">",
"      Kohno S, Kobayashi T, Kakeya H, Miyazaki Y. [Pulmonary aspergilloma, diagnosis and treatment]. Kekkaku 2003; 78:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/21\">",
"      Wollschlager C, Khan F. Aspergillomas complicating sarcoidosis. A prospective study in 100 patients. Chest 1984; 86:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/22\">",
"      Coleman RM, Kaufman L. Use of the immunodiffusion test in the serodiagnosis of aspergillosis. Appl Microbiol 1972; 23:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/23\">",
"      Hagiwara E, Sekine A, Sato T, et al. [Clinical features of chronic necrotizing pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease]. Nihon Kokyuki Gakkai Zasshi 2008; 46:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/24\">",
"      Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/25\">",
"      Kitasato Y, Tao Y, Hoshino T, et al. Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 2009; 14:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/26\">",
"      Park SY, Lee SO, Choi SH, et al. Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. Clin Infect Dis 2011; 52:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22408/abstract/27\">",
"      Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 Suppl 1:S207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2441 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22408=[""].join("\n");
var outline_f21_56_22408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspergilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic cavitary pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic fibrosing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic necrotizing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mycology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Underlying diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Aspergilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic cavitary pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chronic fibrosing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chronic necrotizing pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MONITORING DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2441|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/11/31924\" title=\"diagnostic image 1\">",
"      CPA radiograph and angiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/30/40420\" title=\"diagnostic image 2\">",
"      CPA radiograph and CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/12/24773\" title=\"diagnostic image 3\">",
"      CPA radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/42/16033\" title=\"diagnostic image 4\">",
"      CPA radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/40/31371\" title=\"table 1\">",
"      CPA underlying diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/6/31842?source=related_link\">",
"      Patient information: Chronic pulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_56_22409="Annular lichen planus on penis";
var content_f21_56_22409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53806%7EDERM%2F68197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53806%7EDERM%2F68197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Annular lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A violaceous annular plaque is present on the penile shaft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Annular lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A violaceous annular plaque is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22409=[""].join("\n");
var outline_f21_56_22409=null;
var title_f21_56_22410="Auscultation of heart sounds";
var content_f21_56_22410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Auscultation of heart sounds",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/56/22410/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/56/22410/contributors\">",
"     Kanu Chatterjee, MB, FRCP, FCCP, FACC, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/56/22410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/56/22410/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/56/22410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/56/22410/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/56/22410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular physical examination includes inspection, palpation, and auscultation of the heart as well as examination of the arterial and venous pulses (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    ). The genesis of heart sounds continues to be a subject of debate and the precise mechanisms of their production have not been identified with certainty. This topic will review the auscultation of heart sounds. The auscultation of cardiac murmurs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STETHOSCOPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of stethoscopes are available for auscultation of heart sounds. Many stethoscopes have a separate bell and diaphragm. The bell is most effective at transmitting lower frequency sounds, while the diaphragm is most effective at transmitting higher frequency sounds.",
"   </p>",
"   <p>",
"    Some stethoscopes combine these functions into a single surface such that the intensity of pressure of the stethoscope against the skin determines whether the stethoscope functions as a bell or a diaphragm. In addition, pressing the bell more firmly against the skin alters the frequencies that are loudest towards those of a diaphragm such that higher frequency sounds become louder and lower frequency sounds become softer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FIRST HEART SOUND (S1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic hypothesis for the genesis of the first heart sound (S1), for which there is much support, relates the high-frequency components of S1 to mitral and tricuspid valve closure; the first component of S1 is attributed to mitral valve closure and the second to closure of the tricuspid valve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. A second hypothesis suggests that the principal high-frequency elements of S1 are related to movement and acceleration of blood in early systole, and are influenced by the peak rate of rise of left ventricular (LV) systolic pressure",
"    <span class=\"nowrap\">",
"     (dP/dt),",
"    </span>",
"    which is a measure of contractility and ejection of blood into the root of the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S1 occurs just before or coincident with the upstroke of the carotid pulse. Mitral valve closure precedes the upstroke of the carotid pulse because it occurs before LV ejection begins. However, the delay between mitral valve closure and the upstroke of the carotid pulse normally is too short to be appreciated at the bedside. Tricuspid valve closure normally coincides with the upstroke of the carotid pulse.",
"   </p>",
"   <p>",
"    S1 is best heard with the diaphragm of the stethoscope. The intensity of S1 is primarily determined by the intensity of mitral valve closure and is normally maximal over the cardiac apex. Several factors contribute to the S1 intensity (",
"    <a class=\"graphic graphic_table graphicRef65274 \" href=\"UTD.htm?35/6/35948\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mitral valve position at the onset of systole",
"     </li>",
"     <li>",
"      The rate of mitral valve closure",
"     </li>",
"     <li>",
"      Mobility of the mitral valve",
"     </li>",
"     <li>",
"      The PR interval",
"     </li>",
"     <li>",
"      Strength of ventricular systole",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these factors, such as the rate of mitral valve closure and the strength of ventricular systole, are interrelated; more than one factor may contribute to altered S1 intensity.",
"   </p>",
"   <p>",
"    The intensity of S1 at the bedside is usually based upon a subjective impression. S1 normally is louder than S2 over the apex and along the lower left sternal border; intensity is reduced if S1 is softer than S2 over these areas. S1 intensity is likely to be accentuated if S1 is much louder than S2 over the left or right second interspace.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Increased intensity of S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve closure begins a few milliseconds before onset of the rise of the LV pressure pulse. The intensity of valve closure is increased when the mitral valve remains widely open at end-diastole and then closes rapidly as occurs with an elevated peak rate of rise of left ventricular systolic pressure (peak",
"    <span class=\"nowrap\">",
"     dP/dt).",
"    </span>",
"    The greater distance of travel of the leaflets from the open to the closed position and the increased velocity of closure contribute to the increased intensity of S1. Clinical situations in which this occurs include (",
"    <a class=\"graphic graphic_table graphicRef65274 \" href=\"UTD.htm?35/6/35948\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased transvalvular gradient (mitral valve obstruction as in mitral stenosis or atrial myxoma)",
"     </li>",
"     <li>",
"      Increased transvalvular flow (left-to-right shunt in patent ductus arteriosus, ventricular septal defect, and high output state)",
"     </li>",
"     <li>",
"      Shortened diastole (tachycardia)",
"     </li>",
"     <li>",
"      Short PR intervals (preexcitation syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative contribution of the distance of travel and the velocity of mitral valve closure to increased S1 intensity is difficult to determine; both factors are likely to play a role. When mitral valve closure occurs on the steeper part of the LV pressure pulse, the intensity of S1 increases; this phenomenon may also contribute to an accentuated S1 observed in patients with extremely short PR intervals and left atrial myxoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased intensity of tricuspid valve closure in atrial septal defect and tricuspid valve obstruction (tricuspid stenosis, right atrial myxoma) can also be explained by the same phenomenon. The tricuspid valve is held open by increased transvalvular flow and the transvalvular gradient until final closure with increased velocity occurs with right ventricular (RV) systole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decreased intensity of S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restricted valve mobility and lack of apposition of the valve leaflets decrease the intensity of S1. Thus, S1 is soft when the mitral valve is immobile due to calcification and fibrosis, despite a significant transvalvular gradient. S1 may also be reduced when the leaflets are semi closed prior to the onset of systole or when the velocity of closure is reduced, as can occur with LV dysfunction. These situations are illustrated by the following examples (",
"    <a class=\"graphic graphic_table graphicRef65274 \" href=\"UTD.htm?35/6/35948\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S1 is very soft or absent when mitral regurgitation results from fibrosis and destruction of the valve leaflets (as in patients with rheumatic valve disease), which prevent effective mitral valve closure. In contrast, mitral regurgitation due to perforation of the valve leaflets from bacterial endocarditis may not be associated with a reduced intensity of S1. Similarly, S1 is normal or even accentuated in patients with mitral valve prolapse with late systolic regurgitation. Increased intensity of S1 in some patients with the mitral valve prolapse syndrome may be caused by an increased strength of ventricular systole (hyperkinetic) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced S1 intensity occurs when the mitral valve remains in the semi closed position before the onset of ventricular systole and when the distance of travel and the velocity of valve closure are decreased. S1 is usually soft when the PR interval is prolonged (exceeding 0.2 second) since semi closure of the mitral valve occurs following atrial systole and before ventricular systole begins. Premature closure of the mitral valve can occur in patients with severe acute aortic regurgitation due to a rapid rise in LV diastolic pressure; the mitral valve may be virtually closed at the onset of systole, resulting in a markedly decreased intensity of or even absent S1 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      S1 is soft in some patients with left bundle branch block without any other obvious abnormality; the mechanism is unclear. Decreased valve closure velocity due to myocardial dysfunction is possible.",
"     </li>",
"     <li>",
"      Hemodynamically significant aortic stenosis may be associated with a soft S1; this can occur in the absence of spreading calcification to the mitral valve and in the presence of a normal PR interval [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/9\">",
"       9",
"      </a>",
"      ]. Semi closure of the mitral valve due to a powerful atrial contraction and an abnormally elevated LV diastolic pressure before the onset of ventricular systole is the most likely explanation.",
"     </li>",
"     <li>",
"      S1 is frequently soft in patients with dilated cardiomyopathy, even in the absence of a prolonged PR interval or bundle branch block. The decreased S1 is almost invariably associated with a significantly reduced LV ejection fraction and elevated pulmonary capillary wedge pressure. The mechanism for a soft S1 in these patients remains unclear; semi closure of the mitral valve due to an elevated LV diastolic pressure and decreased velocity of valve closure due to myocardial dysfunction may contribute.",
"     </li>",
"     <li>",
"      Decreased conduction of sounds through the chest wall reduces the intensity of S1 in patients with chronic obstructive pulmonary disease, obesity, and pericardial effusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Variation in the intensity of S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying intensity of S1 may be evident in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is a common feature of atrial fibrillation; the mechanism appears to be a variation in the velocity of valve closure related to changes in the RR cycle length.",
"     </li>",
"     <li>",
"      The intensity of S1 varies in the presence of premature beats.",
"     </li>",
"     <li>",
"      Changing intensity of S1 occurs in atrioventricular dissociation, whether the heart rate is slow or fast (eg, in complete heart block or ventricular tachycardia). The changing intensity is due to random variation of the PR interval; the short PR interval is associated with an increased intensity and the long PR interval with a decreased intensity. The pulse is regular in atrioventricular dissociation; thus, the varying intensity of S1 in a patient with a regular pulse almost always suggests atrioventricular dissociation.",
"     </li>",
"     <li>",
"      Auscultatory alternans, in which S1 is soft and loud with alternate beats, is a rare finding in severe cardiac tamponade; it is almost always associated with electrical alternans and pulsus paradoxus. Although the pulse is regular, changes in the intensity of S1 occur regularly with the alternate beats and not randomly as in atrioventricular dissociation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Splitting of S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are normally two components of S1: the mitral component precedes the carotid pulse upstroke and the tricuspid component occurs later. The interval between mitral and tricuspid closure is 0.02 to 0.03 second and can be appreciated with the diaphragm of the stethoscope along the lower left sternal border [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/1\">",
"     1",
"    </a>",
"    ]. The mitral component is much louder than the tricuspid component and is normally heard more widely across the precordium; the tricuspid component is of low intensity and is best heard over the left third and fourth interspaces close to the sternal border.",
"   </p>",
"   <p>",
"    Abnormal splitting of S1 can result either from conduction disturbances, hemodynamic, or mechanical causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A widely split S1 occurs in complete right bundle branch block, during LV pacing, with ectopic beats of LV origin, and in ventricular tachycardia and idioventricular rhythm when the QRS complex morphology is of right bundle branch block configuration. S2 is also widely split when wide splitting of S1 occurs due to conduction abnormalities, with a further increase in the splitting of S1 and S2 during inspiration; this is due to increased venous return and RV volume with further delay in tricuspid valve closure. A widely split S1 in conduction anomalies results from a delay in onset of the RV pressure pulse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hemodynamic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed closure of the tricuspid valve may occur in patients with atrial septal defect who have large left-to-right shunts. The widely split S1 in this case does not vary with inspiration since the RV volume is fixed despite the increased venous return.",
"   </p>",
"   <p>",
"    Wide splitting of S1 also occurs in patients with significant tricuspid stenosis due to a similar mechanism as in atrial septal defect. Wide splitting of S1 with increased intensity of the second component is a feature of Ebstein's anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/12\">",
"     12",
"    </a>",
"    ]. It is related in part to the commonly associated right bundle branch block.",
"   </p>",
"   <p>",
"    In patients with right atrial myxoma, a delay in closure of the tricuspid valve also causes wide splitting of S1. Wide splitting of S1 resulting from hemodynamic causes may not be associated with wide splitting of S2 (except in atrial septal defect).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pseudo splitting of S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other cardiac sounds that may be confused with a split S1.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relatively loud atrial sound (S4) preceding S1 may be confused with a split S1. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Distinguishing from split S2 or S1'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The combination of a systolic ejection sound (also a high-frequency sound) and S1 may appear as split S1. However, the S1 and ejection sound interval is usually greater than the normal mitral and tricuspid interval. Furthermore, an aortic ejection sound is heard over the cardiac apex, along the left sternal border, and over the right second interspace. In contrast, tricuspid closure is usually heard along the left lower sternal border. Thus, splitting of S1 is not heard over the right or left second interspace.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary ejection sounds can be easily distinguished from tricuspid closure. Pulmonary ejection sounds are usually localized and best heard over the left second interspace. More importantly, pulmonary ejection sounds decrease in intensity during inspiration, while the intensity of tricuspid closure remains unchanged or increases following inspiration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combination of S1 and a midsystolic click is rarely confused with a split S1 since the interval between them is usually far greater than that between mitral and tricuspid valve closure. Furthermore, the S1-click interval can be changed by maneuvers such as standing and squatting, while no significant changes in normal S1 splitting can be appreciated with these maneuvers.",
"     </li>",
"     <li>",
"      The combination of a pacemaker sound and S1 should not be confused with the splitting of S1. The \"pacemaker sound\" that results from the stimulation of the intercostal muscles during pacing has a very high frequency and precedes S1; it therefore occurs well before the upstroke of the carotid pulse [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/13\">",
"       13",
"      </a>",
"      ]. Furthermore, the pacemaker sound disappears with discontinuation of pacing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Reversed splitting of S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversed splitting of S1 (tricuspid component preceding the mitral component) is seldom recognized. It may occur in patients with severe mitral stenosis, in whom mitral valve closure is markedly delayed; in the presence of a left atrial myxoma since mitral valve closure occurs after the tumor is expelled from the LV to the left atrium, resulting in wide and reversed splitting of S1; and with premature beats arising from the RV and associated with a left bundle branch block pattern. In most patients with left bundle branch block, however, reversed splitting of S1 is not appreciated, suggesting that no significant delay in the onset of LV mechanical systole occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SECOND HEART SOUND (S2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genesis of the second heart sound (S2) consists of two components, aortic and pulmonary valve closure sounds, traditionally designated as A2 and P2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/1\">",
"     1",
"    </a>",
"    ]. S2 occurs after the peak of the carotid pulse and coincides with its downslope. The onset of A2 occurs with the dicrotic notch of the aortic root pressure pulse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two components of S2 are best heard with the diaphragm of the stethoscope and over the left second interspace close to the sternal border. A2 is widely transmitted to the right second interspace, along the left and right sternal border, and to the cardiac apex. P2 is normally best heard and recorded over the upper left sternal border and is poorly transmitted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intensity of A2 and P2",
"    </span>",
"    &nbsp;&mdash;&nbsp;S2 is usually single during expiration, particularly when auscultation is performed with subjects in the semi recumbent position. Separation of A2 and P2 occurs during inspiration, allowing comparison of the relative intensities of these two components. A2 is louder, even in pulmonary areas (left second interspace); it is the only component heard over the cardiac apex in almost all normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/16\">",
"     16",
"    </a>",
"    ]. P2 can be heard over the right second intercostal space and along the left sternal border. The relative intensity of A2 is almost always greater than P2 over the left second interspace; the intensity is equal in this area in approximately 2 percent of normal subjects.",
"   </p>",
"   <p>",
"    The major determinants of A2 intensity (and therefore the major determinant of S2) include (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aortic pressure",
"     </li>",
"     <li>",
"      Relative proximity of the aorta to the chest wall",
"     </li>",
"     <li>",
"      Size of the aortic root",
"     </li>",
"     <li>",
"      Degree of apposition of the valve leaflets and their mobility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased intensity of A2 cannot be quantitated objectively by auscultation; it is based upon a subjective impression.",
"   </p>",
"   <p>",
"    The intensity of P2 is determined by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary arterial pressure, particularly the diastolic pressure",
"     </li>",
"     <li>",
"      Size of the pulmonary artery",
"     </li>",
"     <li>",
"      Degree of apposition of the pulmonary valve leaflets",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intensity of P2 is determined by comparing its intensity with A2. An increased P2 intensity is suggested when it is louder over the left second interspace or when there is transmission to the cardiac apex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Increased intensity of A2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intensity of A2 often occurs in systemic hypertension, coarctation of the aorta, and ascending aortic aneurysm; a \"tambour\" quality of A2 is commonly heard (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    ). The intensity of A2 is significantly increased when the aortic root is relatively anterior and closer to the anterior chest wall, as in tetralogy of Fallot and transposition of the great arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Increased intensity of P2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of an increased P2 intensity is pulmonary arterial hypertension of any etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/17\">",
"     17",
"    </a>",
"    ]. A2 is soft in patients with mitral regurgitation and P2 may appear to be increased. In these circumstances, one cannot rely on the relative intensity of P2 for the diagnosis of pulmonary hypertension.",
"   </p>",
"   <p>",
"    In atrial septal defect the intensity of P2 is increased considerably and frequently greater than A2 over the left second interspace, even with a normal or slightly elevated pulmonary artery pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/18\">",
"     18",
"    </a>",
"    ]. P2 is heard over the cardiac apex in 50 percent of these patients. The mechanism for the increased intensity of P2, despite low pulmonary artery diastolic pressure and pulmonary vascular resistance, is unclear. A dilated pulmonary artery and considerable RV dilatation may contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Decreased intensity of A2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased intensity of A2 occurs when there is lack of apposition of the valve leaflets, as in severe luetic aortic regurgitation. Other causes of decreased A2 intensity include lower arterial diastolic pressure (eg, in significant aortic regurgitation), a relatively immobile aortic valve due to calcification (eg, in patients with calcific aortic stenosis), and relatively lower arterial pressure in hemodynamically significant aortic stenosis (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Decreased intensity of P2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decreased intensity of P2 occurs when there is lower pulmonary artery diastolic pressure, except with atrial septal defect. P2 is soft and delayed with significant RV outflow obstruction, as in patients with pulmonary valve stenosis. P2 is absent in patients with severe pulmonary insufficiency due to a congenitally absent pulmonary valve. In contrast, P2 is markedly accentuated in pulmonary insufficiency secondary to pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Splitting of S2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspiratory splitting of S2 can be appreciated 24 to 48 hours after birth when the pulmonary vascular resistance is considerably lower than at birth. A2 and P2 are usually fused during the expiratory phase of continuous respiration when auscultation is performed in adults in the semi recumbent position (30&ordm; to 40&ordm; from the horizontal); occasionally, slight expiratory splitting is heard in the recumbent position. During the inspiratory phase, separation of A2 and P2 occurs; the degree of splitting varies from 0.02 to 0.06 second [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/19\">",
"     19",
"    </a>",
"    ]. Splitting of S2 is best heard with the diaphragm of the stethoscope over the left second interspace.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple mechanisms contribute to the normal inspiratory splitting of S2. A2, which is coincident with the incisura of the aortic pressure pulse, occurs on average 0.02 seconds after LV systolic pressure falls below the aortic pressure. P2, coincident with the pulmonary arterial incisura, occurs 0.03 to 0.09 seconds after the crossover point of RV and central pulmonary arterial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interval between the pressure crossover point and the incisura (the onset of A2 or P2) has been termed hangout time. The hangout time is inversely proportional to the impedance to blood flow in the systemic arterial and pulmonary arterial systems. Systemic vascular resistance normally is considerably higher than pulmonary vascular resistance and systemic arteries are less compliant than the pulmonary arteries. These differences account for the shorter hangout time in the aorta than in the pulmonary artery. During inspiration, pulmonary vascular impedance declines with a further increase in the pulmonary hangout time, which appears to be the principal mechanism for inspiratory splitting of S2.",
"   </p>",
"   <p>",
"    The other contributions to a normal inspiratory splitting of S2 result from an increased RV ejection time. More negative intrathoracic pressure during inspiration is associated with increased venous return to the RV and greater RV stroke volume, which increases its ejection time and delays P2. Inspiratory delay of aortic valve closure is minimal, probably due to a much shorter aortic compared with pulmonary hangout time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. After one to three cardiac cycles the immediate inspiratory increase in RV stroke volume is followed by a similar increase in LV stroke volume, associated with increased LV ejection time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/24\">",
"     24",
"    </a>",
"    ]. Prolongation of the LV ejection time and a delayed A2 during normal respiration usually occur during the expiratory phase, while lengthening of the right ventricular ejection time and delayed pulmonary valve closure coincide with the inspiratory phase.",
"   </p>",
"   <p>",
"    The relative contributions of these different mechanisms to the normal inspiratory splitting of S2 are difficult to determine. Traditionally, it has been thought that prolongation of the RV ejection time accounts for a major part of the normal inspiratory splitting. Recent studies, however, suggest that the increase in pulmonary hangout time is the major contribution to normal inspiratory splitting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Wide splitting of S2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A2 and P2 are fused in normal adults and S2 appears single during the expiratory phase of respiration, particularly in the semi recumbent, sitting, and standing positions. Wide splitting of S2 should be suspected if the A2-P2 separation is appreciated in these positions during expiration. The A2-P2 interval needs to be 0.03 second or more to be appreciated by auscultation at the bedside.",
"   </p>",
"   <p>",
"    A wide splitting of S2 can result either from conduction disturbances or hemodynamic causes (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55198 \" href=\"UTD.htm?3/58/4007\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conduction disturbances &mdash; Conduction anomalies that cause wide splitting of S2 include complete right bundle branch block, artificial pacing from the LV, and the Wolff-Parkinson-White syndrome with LV preexcitation. Premature beats and an idioventricular rhythm of LV origin (QRS complex of right bundle branch block morphology) are also associated with wide splitting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Wide splitting of S2 due to conduction disturbances results from delayed activation of the RV and, consequently, delayed completion of right ventricular ejection. Widened splitting of S2 during inspiration and concomitant splitting of S1 occur in these circumstances.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic causes &mdash; Increased resistance to right ventricular ejection and prolongation of right ventricular ejection time are other important causes of wide expiratory splitting of S2. Pulmonary valve and infundibular stenosis, supravalvular and pulmonary branch stenoses, and pulmonary arterial hypertension of any etiology lengthen right ventricular ejection time and cause relatively wide splitting of S2. The intensity of P2 is related to the pulmonary arterial diastolic pressure; a lower pressure is associated with a reduced intensity and a higher pressure with increased intensity. Thus, in patients with pulmonary valve and infundibular stenoses, wide splitting of S2 is associated with reduced intensity of P2, while P2 is accentuated in pulmonary hypertension and pulmonary branch stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In pulmonary valve stenosis, the degree of expiratory splitting of S2 (the A2-P2 interval) is directly related to the severity of stenosis and right ventricular systolic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/25\">",
"     25",
"    </a>",
"    ]. Further splitting of S2 during inspiration usually occurs in these conditions, but wide splitting of S1 is not observed.",
"   </p>",
"   <p>",
"    Although expiratory splitting is obvious in pulmonary hypertension, the degree of splitting is much less than in other conditions which also increase the resistance to RV ejection. This is because of a significant reduction in pulmonary hangout time due to decreased pulmonary vascular compliance in pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/20\">",
"     20",
"    </a>",
"    ]. For the same reason, the magnitude of inspiratory widening of the splitting of S2 is smaller. Thus, in patients with chronic pulmonary arterial hypertension, a relatively narrow expiratory splitting of S2 is expected with only a slight inspiratory increase.",
"   </p>",
"   <p>",
"    Isolated reduction of the LV ejection time may also cause wide splitting of S2 due to the early occurrence of A2. The best example is significant mitral regurgitation, which decreases impedance to left ventricular ejection and forward stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/26\">",
"     26",
"    </a>",
"    ]. In some patients with a ventricular septal defect with increased pulmonary flow and decreased pulmonary vascular resistance, wide splitting of S2 can occur due to the same mechanism, although a delay in the onset of right ventricular mechanical systole has also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/27\">",
"     27",
"    </a>",
"    ]. Inspiratory widening of S2 is maintained in patients in this category, and S1 usually remains normal. Inspiratory reduction in LV ejection time can also occur in constrictive pericarditis, which may account for the wide inspiratory splitting of S2 that occasionally is observed in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Wide and \"fixed\" splitting of S2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed splitting of S2 has been defined as &le;20 msec of variation in the A2-P2 interval between the inspiratory and expiratory phases of respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/18\">",
"     18",
"    </a>",
"    ]. However, such limitation in variation of splitting may be difficult to discern clinically, so wide and variable splitting may be difficult to distinguish from wide and fixed splitting.",
"   </p>",
"   <p>",
"    One common cause of wide and fixed splitting of S2 is a large interatrial communication (atrial septal defect, common atrium) and left-to-right or bidirectional shunt; abnormally wide splitting of S2 occurs and respiratory variations of the A2-P2 intervals are minimal or absent. The mechanism of wide expiratory splitting of S2 in atrial septal defect appears to result from isolated shortening of LV ejection time while the RV ejection time remains normal, and an increase in pulmonary hangout time due to decreased pulmonary vascular impedance (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/18,29\">",
"     18,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other cause of fixed splitting of S2 is RV failure, when the right ventricle is unable to vary its stroke volume during inspiration, and inspiratory prolongation of its ejection time and delay of P2 does not occur. Therefore, any condition that induces severe RV failure, such as right ventricular outflow obstruction, pulmonary hypertension, and primary RV dysfunction can be associated with fixed splitting (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Reversed (paradoxic) splitting of S2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paradoxic splitting occurs when A2 follows P2 during the expiratory phase of respiration. The splitting of S2 is then maximal during expiration and the splitting is less or S2 becomes single during inspiration with the normal inspiratory delay of P2 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/1,30\">",
"     1,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reversed splitting of S2 may result from either conduction disturbances or hemodynamic causes (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conduction abnormalities &mdash; Left bundle branch block, artificial RV pacing, preexcitation of the RV (Wolff-Parkinson-White syndrome), and premature beats of RV origin are examples of conduction disturbances associated with reversed splitting of S2. Delayed activation of the LV, and consequently delayed completion of LV ejection, causes a delayed A2 and reversed splitting of S2. In left bundle branch block or the preexcitation syndrome, splitting of S1 does not usually occur. Splitting of S1, however, may accompany splitting of S2 with RV pacing or ectopic beats. With a lesser degree of left bundle branch block or right ventricular preexcitation, the P2-A2 interval during expiration may be very short (reversed splitting), and normal splitting can occur during inspiration.",
"     </li>",
"     <li>",
"      Hemodynamic factors &mdash; A markedly prolonged LV ejection time may delay A2 sufficiently to cause reversed splitting of S2. With fixed LV outflow tract obstruction, as in patients with aortic valve stenosis, LV ejection time is lengthened and reversed splitting of S2 usually indicates hemodynamically significant outflow obstruction. However, P2 may be inaudible due to the long ejection systolic murmur of aortic stenosis, making it difficult to recognize the reversed splitting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between hypertrophic cardiomyopathy and mitral regurgitation or ventricular septal defect, conditions in which the character and locations of the systolic murmur may appear similar on auscultation, is facilitated by recognizing the character of S2 splitting. Reversed splitting suggests hypertrophic cardiomyopathy, while physiologic splitting favors mitral regurgitation or ventricular septal defect.",
"   </p>",
"   <p>",
"    Reversed splitting of S2 is observed in some patients with hypertension. However, the P2-A2 interval in expiration is usually short and normal inspiratory splitting occurs.",
"   </p>",
"   <p>",
"    A prolonged LV ejection time and reversed splitting of S2 can occur with myocardial dysfunction, as in myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/31\">",
"     31",
"    </a>",
"    ]. However, reversed splitting is rarely observed with severe heart failure because of the concomitant decrease in stroke volume, which is an important determinant of LV ejection time.",
"   </p>",
"   <p>",
"    A selective increase in LV forward stroke volume may prolong LV ejection time sufficiently to cause reversed splitting of S2; this explains reversed splitting of S2 in some patients with patent ductus arteriosus with a large left-to-right shunt and in patients with significant chronic aortic regurgitation. Reversed splitting of S2 is often difficult to recognize by auscultation because the inspiratory noise often obscures a relatively soft P2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Single S2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single S2 may result from the absence of either of the two components of S2 or from the fusion of A2 and P2 without inspiratory splitting (",
"    <a class=\"graphic graphic_table graphicRef77038 \" href=\"UTD.htm?14/33/14877\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of A2 is occasionally observed in severe calcific aortic stenosis with an immobile aortic valve. A2 may be absent in some patients with severe aortic regurgitation due to destruction of the valve leaflets.",
"     </li>",
"     <li>",
"      P2 is absent in the congenital absence of the pulmonary valve, pulmonary atresia, and truncus arteriosus. In severe pulmonary valve stenosis or in tetralogy of Fallot, P2 may be markedly attenuated and escape recognition by auscultation.",
"     </li>",
"     <li>",
"      Fusion of A2 and P2 without inspiratory splitting occurs in Eisenmenger syndrome with ventricular septal defect and in patients with a single ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A truly single S2 is rare. An apparently single S2 usually results from the inability to hear or record P2 due to emphysema, obesity, or pericardial effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     THIRD (S3) AND FOURTH (S4) HEART SOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;S3 and S4 are low-frequency diastolic sounds that appear to originate in the ventricles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of the genesis of S3 and S4 has not been identified with certainty. It is generally agreed that both sounds, occasionally termed ventricular filling sounds, are associated with ventricular filling and an increase in ventricular dimensions. They are heard and recorded during rapid filling and atrial filling phases of the ventricle, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S3 occurs as passive ventricular filling begins after actual relaxation is completed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/33\">",
"       33",
"      </a>",
"      ]. It appears to be related to a sudden limitation of the movement during ventricular filling along its long axis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/34\">",
"       34",
"      </a>",
"      ]. It coincides with the y descent of the atrial pressure pulse and the end of the rapid filling phase of the apical impulse, occurring usually 0.14 to 0.16 second after S2.",
"     </li>",
"     <li>",
"      S4 occurs after the P wave on the electrocardiogram and coincides with atrial systole and a waves of the atrial pressure pulse, and with the apical impulse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Auscultation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;S3 and S4 are best heard with the bell of the stethoscope. Auscultation over the cardiac apex in the left lateral decubitus position is preferable for identification of left ventricular S3 and S4. Right ventricular S3 and S4 are best heard along the lower left sternal border; occasionally right-sided filling sounds are also heard over the lower right sternal border and over the epigastrium. The intensity of S3 and S4 of right ventricular origin usually increases during inspiration, while that of left ventricular origin remains unchanged. S3 is closer to S2 and S4 occurs prior to S1.",
"   </p>",
"   <p>",
"    S3 can be heard and recorded in healthy young adults. However, it is usually abnormal in patients over the age of 40 years, suggesting an enlarged ventricular chamber.",
"   </p>",
"   <p>",
"    S4 can be heard in many healthy older adults without any other cardiac abnormality due to decreased ventricular compliance with age. S4 may become audible in otherwise healthy subjects with a prolonged PR interval due to the separation of S4 from S1. In patients with complete atrioventricular block, S4 is heard at a faster rate than S1 and S2 and may not indicate any hemodynamic abnormality. S4 is usually abnormal in young adults and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Distinguishing from split S2 or S1",
"    </span>",
"    &nbsp;&mdash;&nbsp;S3 and S4 may be confused with a split S2 and split S1, respectively. When split, the two parts of S1 or S2 typically have a similar pitch, while S3 and S4 are lower pitched sounds than S2 and S1.",
"   </p>",
"   <p>",
"    This difference in pitch can be brought out by listening with the bell and the diaphragm of the stethoscope. The lower pitched S3 and S4 will be more pronounced when listening gently with the bell, while the higher pitched split S1 and S2 will be more pronounced when listening with the diaphragm or when applying the bell more firmly to the skin. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Stethoscopes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Auscultation to distinguish S3 and S4 from splitting of S2 and S1 is best performed in the 45 degree left lateral decubitus position (ie, with the chest rotated toward the examining table). The location of the sound is useful in distinguishing S4 from a split S1. The left ventricular S4 is usually localized over the cardiac apex, and becomes softer as the bell of the stethoscope is moved gradually to the left sternal border.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Gallops",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal S3 and S4 tend to be louder and of higher pitch (sharper) and are frequently referred to as gallops. S3 is the ventricular gallop and S4 is the atrial gallop sound. S3 and S4 can be fused during tachycardia to produce a loud diastolic filling sound, termed a summation gallop [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/35\">",
"     35",
"    </a>",
"    ]. At the bedside, carotid massage can cause separation of S3 and S4 as the heart rate slows. S3 and S4 may occasionally be intensified or precipitated by exercise or by sustained hand grip. Gallops can sometimes be seen and palpated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective atrial contraction and ventricular filling are both required for production of atrial gallop sounds. Thus, these sounds are usually absent in atrial fibrillation and in significant atrioventricular valve stenosis.",
"   </p>",
"   <p>",
"    It is often difficult to distinguish between gallop sounds of right and left ventricular origin at the bedside when they are present in the same patient. However, if one follows the \"inching\" method of auscultation (eg, auscultation starting over the cardiac apex and then gradually moving the stethoscope inch-by-inch to the left lower sternal border), the decreasing intensity of gallops of left ventricular origin and the increasing intensity of gallops of right ventricular origin can be appreciated. Furthermore, the intensity of the right-sided gallop sounds increase during inspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Left ventricular gallops",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S3 gallop &mdash; An S3 gallop is almost always present in patients with hemodynamically significant chronic mitral regurgitation; the absence of S3 is an important finding to exclude severe chronic mitral regurgitation. An S3 gallop in patients with chronic aortic regurgitation is frequently associated with a decreased left ventricular ejection fraction and increased diastolic volume; its recognition should prompt further evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An S3 gallop is an important and common early finding of heart failure associated with dilated cardiomyopathy and may also be heard in patients with diastolic heart failure (although less frequently than with systolic heart failure), aortic valve disease, and coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/37\">",
"     37",
"    </a>",
"    ]. In such patients, an S3 gallop is usually associated with left atrial pressures exceeding 20 mmHg, increased left ventricular end-diastolic pressures (&gt;15 mmHg) and elevated serum brain natriuretic peptide concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic test characteristics of the S3 and S4 for detection left ventricular dysfunction was evaluated in a phonocardiographic study of patients who were undergoing cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/40\">",
"     40",
"    </a>",
"    ]. These sounds were not very sensitive (40 to 50 percent) for the detection of an elevated left ventricular end-diastolic pressure or a reduced left ventricular ejection fraction; however, the S3 was highly specific (90 percent) for these parameters and for an elevated serum brain natriuretic peptide concentration. An additional problem is appreciable interobserver variability in the ability to detect an S3 on cardiac auscultation that cannot be solely explained by the experience of the observer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of an S3 gallop also has prognostic significance, being associated with a higher risk of progression to symptomatic heart failure in those with asymptomatic left ventricular dysfunction and a higher risk of hospitalization for heart failure or death from pump failure in patients with overt heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. One limitation to these observations is the operator-dependence for the detection of this physical finding.",
"   </p>",
"   <p>",
"    An S3 often occurs in high-output states such as thyrotoxicosis or pregnancy. In these settings, it does not necessarily indicate left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S4 gallop &mdash; An audible S4 is abnormal in younger subjects and children; it is always abnormal when it is palpable, regardless of patient age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An abnormal S4 is most frequently observed in patients with decreased left ventricular distensibility [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, S4 is common in hypertensive heart disease, aortic stenosis, and hypertrophic cardiomyopathy. Left ventricular hypertrophy, which is present in all these conditions, contributes to decreased left ventricular distensibility.",
"   </p>",
"   <p>",
"    In aortic stenosis, the presence of an S4 has been reported to indicate hemodynamically significant left ventricular outflow obstruction, with a peak transvalvular gradient &ge;70 mmHg and an elevated left ventricular end-diastolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/47\">",
"     47",
"    </a>",
"    ]. However, in patients over 40 years of age, S4 can occur due to myocardial disease in the absence of significant aortic stenosis. Thus, in elderly patients, the presence of an S4 cannot be used to assess the severity of aortic stenosis. Associated coronary artery disease may also cause an S4 in patients with mild to moderate aortic stenosis.",
"   </p>",
"   <p>",
"    An S4 is heard in the vast majority of patients during the acute phase of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/48\">",
"     48",
"    </a>",
"    ]. Although pulmonary venous pressure may also be elevated, there is a poor correlation between the presence and absence of an S4 and hemodynamic abnormalities. Thus, S4 is a poor guide to assess the severity of left ventricular dysfunction in patients with acute myocardial infarction.",
"   </p>",
"   <p>",
"    Audible",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palpable atrial gallops are a frequent finding in chronic left ventricular aneurysm and are usually found with left ventricular dyskinesia associated with elevated end-diastolic pressures. In patients with chronic coronary artery disease, the transient appearance of an S4, particularly during chest pain, is a strong indication of transient myocardial ischemia.",
"   </p>",
"   <p>",
"    A loud S4 that is also usually palpable is a frequent finding in patients with acute and severe mitral or aortic regurgitation. It is almost always associated with an increased left ventricular end-diastolic pressure (&gt;15 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/49\">",
"     49",
"    </a>",
"    ]. The predictive value is increased in the presence of both S3 and S4 gallops [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Right ventricular gallops",
"    </span>",
"    &nbsp;&mdash;&nbsp;An S3 gallop of right ventricular origin frequently occurs in patients with significant tricuspid regurgitation, whether it is primary or secondary to pulmonary hypertension and right ventricular failure. An S3 gallop is also heard in right ventricular failure in the absence of tricuspid regurgitation.",
"   </p>",
"   <p>",
"    An S4 of right ventricular origin is most commonly heard in patients with right ventricular outflow obstruction (pulmonary valve stenosis) and pulmonary arterial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/50\">",
"     50",
"    </a>",
"    ]. It likely denotes decreased right ventricular distensibility due to hypertrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PERICARDIAL KNOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular filling is confined to early diastole in constrictive pericarditis and terminates with a sharp S3; this is termed a pericardial knock. Its timing is earlier than a normal S3 and typically occurs 0.10 to 0.12 second after S2. It is a common finding in constrictive pericarditis and can occur with or without pericardial calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/51\">",
"     51",
"    </a>",
"    ]. It is occasionally heard only during inspiration and along the lower right sternal border, suggesting an early manifestation of right ventricular constriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     EJECTION SOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aortic ejection sound is a high-frequency \"clicky,\" early systolic sound, usually recorded 0.12 to 0.14 second after the Q wave on the electrocardiogram. It is best heard with the diaphragm of the stethoscope and is widely transmitted, heard at the cardiac apex and also over the right second interspace. Its intensity does not vary with respiration.",
"   </p>",
"   <p>",
"    When aortic or pulmonary ejection sounds occur in the presence of normal semilunar valves, the origin may be the proximal aortic or pulmonary artery segments. Thus, the term vascular ejection sound has been suggested. These sounds generally tend to occur later and are not associated with \"doming\" of the semilunar valves, which is characteristic of a valvular ejection sound. The mechanism of the vascular ejection sound remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Aortic ejection sound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic ejection sounds occur in association with a deformed but mobile aortic valve and with aortic root dilatation. Thus, it is present in aortic valve stenosis, bicuspid aortic valve, aortic regurgitation, and with aneurysm of the ascending aorta. An aortic ejection sound is also heard in some patients with systemic hypertension, probably due to associated aortic root dilatation.",
"   </p>",
"   <p>",
"    Aortic ejection sounds are heard frequently in patients with mild to moderate aortic valve stenosis; they may be absent in severe calcific aortic stenosis, presumably due to the loss of valve mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/52\">",
"     52",
"    </a>",
"    ]. Since ejection sounds are usually absent in subvalvular and supravalvular aortic stenosis, the presence of an ejection sound helps to identify the site of obstruction at the level of the aortic valve. An ejection sound also does not favor the diagnosis of hypertrophic cardiomyopathy.",
"   </p>",
"   <p>",
"    Identification of the aortic ejection sound is the most important and consistent bedside clue for the diagnosis of an uncomplicated bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/53\">",
"     53",
"    </a>",
"    ]. In patients with coarctation of the aorta, an aortic ejection sound usually signifies the presence of an associated bicuspid aortic valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Pulmonary ejection sound",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pulmonary ejection sound occurs earlier than an aortic ejection sound and is recorded 0.09 to 0.11 second after the Q wave on the electrocardiogram, beginning at the time of maximal opening of the pulmonary valve. It is also a \"clicky\" sound of high frequency and is best heard with the diaphragm of the stethoscope. In contrast to the aortic ejection sound, it is not widely transmitted and usually best heard at the left second interspace and along the left sternal border; it is not usually heard over the cardiac apex or right second interspace.",
"   </p>",
"   <p>",
"    The most helpful distinguishing feature of a pulmonary ejection sound is its decreased intensity, or even its disappearance during the inspiratory phase of respiration. During expiration, the valve opens rapidly from its fully closed position; sudden \"halting\" of this rapid opening movement is associated with a maximal intensity of the ejection sound. With inspiration, the increased venous return to the right ventricle augments the effect of right atrial systole and causes partial opening of the pulmonary valve prior to ventricular systole. The lack of a sharp opening movement of the pulmonary valve explains the decreased intensity of the pulmonary ejection sound during inspiration.",
"   </p>",
"   <p>",
"    The tricuspid closure sound should not be confused with the pulmonary ejection sound. The intensity of tricuspid closure sound tends to increase rather than decrease during inspiration.",
"   </p>",
"   <p>",
"    Pulmonary ejection sounds tend to be present in clinical conditions associated with a deformed pulmonary valve and pulmonary artery dilatation, including pulmonary valve stenosis, idiopathic dilatation of the pulmonary artery, and chronic pulmonary arterial hypertension of any etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. The interval between the S1 and the pulmonary ejection sound is directly related to the right ventricular isovolumic contraction time, which usually is prolonged in pulmonary hypertension, explaining a relatively late occurrence of the ejection sound in these patients. With increasing severity of pulmonary valve stenosis, the isovolumic systolic interval shortens, and the pulmonary ejection sound therefore tends to occur soon after S1. In patients with very severe pulmonary valve stenosis, the ejection sound can fuse with S1 and may not be recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     NON-EJECTION SYSTOLIC SOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-ejection systolic sounds are also high-frequency sounds that occur much later after S1 and are best heard with the diaphragm of the stethoscope. These sounds are not widely transmitted and not usually heard over the right or left second interspace.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Midsystolic click",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse of the mitral valve is the most common cause for a non-ejection midsystolic click; the timing coincides with maximal prolapse of the mitral valve into the left atrium. It may or may not be associated with a late systolic murmur (",
"    <a class=\"graphic graphic_movie graphicRef57858 \" href=\"UTD.htm?7/55/8051\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80360 \" href=\"UTD.htm?15/40/16004\">",
"     movie 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the click occurs early in systole it can be confused with the ejection sound or the second component of a widely split S1. A number of bedside maneuvers can be performed to confirm the presence of a midsystolic click. These maneuvers are based upon the fact that the systolic dimension or volume at which mitral valve prolapse and the click occurs tends to remain fixed in the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, whenever the \"click\" volume or dimension is reached following the onset of ventricular ejection (corresponding roughly to S1), a midsystolic click occurs. The S1-click interval, then, can vary according to the preejection (end-diastolic) ventricular volume and the rate of ejection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The S1-click interval will increase, producing a late midsystolic click, whenever there is an increase in end-diastolic volume (supine position, squatting, hand grip) (",
"      <a class=\"graphic graphic_movie graphicRef80360 \" href=\"UTD.htm?15/40/16004\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The S1-click interval usually shortens and the click tends to occur earlier when there is a reduction in end-diastolic volume (standing, phase 2 Valsalva maneuver,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/1/33813?source=see_link\">",
"       amyl nitrite",
"      </a>",
"      ) or when there is an increased rate of ejection as occurs after an ectopic beat as a result of post ectopic potentiation (",
"      <a class=\"graphic graphic_movie graphicRef57858 \" href=\"UTD.htm?7/55/8051\">",
"       movie 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to identify the other cardiovascular anomalies that may accompany mitral valve prolapse, including Marfan's syndrome, atrial septal defect (secundum or primum), musculoskeletal abnormalities, systemic lupus erythematosus, hypertrophic cardiomyopathy, and pseudohypertrophic muscular dystrophy. When no obvious association is identified, the idiopathic mitral valve prolapse syndrome is diagnosed, which has been variously termed as Barlow's syndrome, billowing mitral valve, or floppy valve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tricuspid valve prolapse also produces high-frequency midsystolic, \"clicky\" sounds; these are best heard with the diaphragm of the stethoscope over the lower left sternal border and occasionally over the lower right sternal border. The interval between S1 and the tricuspid valve click tends to increase following inspiration and after raising the legs and other maneuvers that increase right ventricular volume. Isolated tricuspid valve prolapse occurs only rarely, and in most instances it accompanies mitral valve prolapse. Tricuspid valve prolapse, however, may occur in the absence of mitral valve prolapse in patients with Ebstein's anomaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Precordial honk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systolic \"whoop\" or \"precordial honk\" are short musical systolic murmurs often preceded by a click and occurring in mid or late systole. These sounds can be transient, occur only in certain positions, or may be precipitated by exercise. Mitral valve prolapse is the cause for the \"whoop\" or \"honk\" in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Pseudo-ejection sound",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonejection sound has been observed to occur in some patients with hypertrophic cardiomyopathy, associated with systolic anterior motion of the anterior mitral leaflet. This sound has been termed a pseudo-ejection sound [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/65\">",
"     65",
"    </a>",
"    ]. Unlike the ejection click of aortic stenosis, this sound begins considerably after the upstroke of the carotid pulse. The precise mechanism of the pseudo-ejection sound in hypertrophic cardiomyopathy remains unclear. It may either result from contact of the anterior leaflet with the septum or from the deceleration of blood flow in the left ventricular outflow tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     EARLY DIASTOLIC HIGH-FREQUENCY SOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes for sounds occurring in diastole include the opening snap of the mitral or tricuspid valve or a tumor plop associated with an atrial myxoma (",
"    <a class=\"graphic graphic_table graphicRef73281 \" href=\"UTD.htm?13/16/13579\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Opening snap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opening snap is a high-frequency, early diastolic sound associated with mitral or tricuspid valve opening. This opening of the atrioventricular valves, which is normally silent, becomes audible in the presence of pathologic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Mitral valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis is the most frequent and important cause of an opening snap. It can occur rarely in patients with pure mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/49,66\">",
"     49,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The opening snap is best heard with the diaphragm of the stethoscope, medial to the cardiac apex. It is usually widely transmitted and can be easily heard over the left second interspace and along the left sternal border. The opening snap coincides with the full opening of the mitral valve and occurs 0.04 to 0.12 second after S2 (",
"    <a class=\"graphic graphic_movie graphicRef55136 \" href=\"UTD.htm?7/25/7571\">",
"     movie 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The opening snap can easily be confused with a split S2 since it is frequently transmitted to the left second interspace. However, careful auscultation over the left second interspace, in the supine position and during both phases of respiration, reveals three high-frequency sounds in close proximity to each other during inspiration; the initial two are the two components of S2, and the third is the opening snap. The recognition of these three sounds during inspiration helps to differentiate mitral stenosis, as seen in mitral valve obstruction, from atrial septal defect, which may also be associated with a mid-diastolic rumble. In atrial septal defect, only the two components of the S2 are heard during expiration and inspiration.",
"   </p>",
"   <p>",
"    The opening snap results from rapid opening of the mitral valve to its maximal open position; thus, mobility of the valve contributes to its genesis. It is absent when the mitral valve is heavily calcified and immobile. However, the opening snap is heard in the vast majority of patients with mitral stenosis, and along with an accentuated S1, frequently provides the first clue to the diagnosis.",
"   </p>",
"   <p>",
"    The severity of mitral stenosis can be assessed at the bedside by noting the interval between the aortic component of S2 and the opening snap. The S2-opening snap interval is related to the difference in pressures at the time of aortic valve closure and the opening of the mitral valve, which occurs during the isovolumic relaxation phase when the left ventricular pressure falls below the left atrial pressure. When mitral stenosis is severe, left atrial pressure is higher and the pressure crossover point between the left ventricle and left atrium is closer to S2, which reduces the S2-opening snap interval. At the bedside, the shorter S2-opening snap interval sounds like a widely split S2.",
"   </p>",
"   <p>",
"    The S2-opening snap interval is not only related to the height of the left atrial pressure but also to aortic valve closing pressure. Thus, with a higher aortic valve closing pressure (systemic hypertension) and earlier closure of the aortic valve, the S2-opening snap interval may be longer with the same degree of elevation of left atrial pressure. Similarly, when the aortic valve dosing pressure is lower (aortic regurgitation and aortic stenosis), aortic valve closure is later and the S2-opening snap interval becomes shorter with the same degree of mitral stenosis. The S2-opening snap interval also becomes shorter when mitral stenosis is associated with mitral regurgitation with a large v wave. Furthermore, tachycardia decreases the S2-opening snap interval as the left atrial pressure increases with increasing heart rate in mitral stenosis. Thus, assessment of the severity of mitral stenosis by estimating the S2-opening snap interval alone should be done with caution in the presence of tachycardia, hypertension, mitral regurgitation, and aortic valve disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Tricuspid valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricuspid valve stenosis may be associated with a tricuspid valve opening snap that is not widely transmitted and is heard best over the lower left sternal border. The tricuspid opening snap can also be heard in some patients with an atrial septal defect and a large left-to-right shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Tumor plop",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diastolic sounds (tumor \"plop\") are occasionally heard in atrial myxoma. These sounds appear to occur when tumors move into the ventricle and come to a sudden halt [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7936863\">",
"    <span class=\"h2\">",
"     Vegetation plop",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetation plop is an early diastolic sound that is occasionally heard in bacterial endocarditis. It appears that this sound is produced when a large vegetation attached to mitral valve leaflet enters the left ventricle during early diastole [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high-frequency, diastolic sound can be heard in other conditions and should be differentiated from the opening snap or tumor plop.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some patients with mitral valve prolapse, a high-frequency sound is heard in early diastole that appears to be related to the rapid inward movement of the prolapsed mitral valve toward the left ventricular cavity before the opening of the mitral valve [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/69\">",
"       69",
"      </a>",
"      ]. This early diastolic sound should not be confused with an opening snap due to mitral stenosis.",
"     </li>",
"     <li>",
"      In some patients with hypertrophic cardiomyopathy who have a small left ventricular cavity size, early diastolic high-frequency sounds are heard coinciding with the time of contact of the anterior leaflet of the mitral valve to the interventricular septum [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-frequency early diastolic sounds, similar to the opening snap, can be heard in some patients with severe mitral regurgitation due to ruptured chordae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     ARTIFICIAL VALVE SOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various types of prosthetic and tissue valves that are in use for valve replacement may produce both opening and closing sounds. The relative intensity of the opening and closing sounds vary according to the type and design of the prosthetic valve used (",
"    <a class=\"graphic graphic_table graphicRef61951 \" href=\"UTD.htm?31/14/31980\">",
"     table 4",
"    </a>",
"    ). The artificial valve sounds are of high frequency, are much louder than normal valve sounds, and are of a \"clicky\" character. The opening or closing sound may consist of multiple clicks, which do not necessarily indicate valve malfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The closing sound is generally louder than the opening sound with a disk valve.",
"     </li>",
"     <li>",
"      Both the opening and closing sounds are loud with the ball and cage type of valve.",
"     </li>",
"     <li>",
"      The closing sounds of the porcine valve are much louder than the opening sounds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Ball variance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ball variance is a term used to describe certain physical changes in a cage ball and is associated with changes in the intensity of opening and closing sounds [",
"    <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/71\">",
"     71",
"    </a>",
"    ]. Ball variance was related to a specific model of the caged ball type of prosthetic valve, which is rarely used at the present time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Valve malfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the normal sounds produced by the prosthetic valve may indicate valve malfunction. However, malfunction of an artificial valve can exist despite a normal intensity or character of the opening or closing sounds. Doppler echocardiography and cardiac catheterization are usually necessary to establish this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link\">",
"     \"Management of patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The closing sound is usually louder than the opening sound regardless of the type of prosthetic valve used. A decreased intensity of the closing sound should raise the possibility of malfunction of the artificial valve.",
"     </li>",
"     <li>",
"      The absence of an opening click has been found in dehiscence of a mitral valve prosthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obstruction of a prosthetic valve in the mitral position may be associated with a markedly decreased S2-opening sound interval. A marked variation in the S2-mitral prosthesis opening sound may indicate malfunction of the Bjork-Shiley mitral prosthesis. The variation in this interval usually does not exceed 25 msec with a normally functioning prosthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     PERICARDIAL FRICTION RUB AND OTHER ADVENTITIOUS SOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pericardial rub is generated by the friction of two inflamed layers of the pericardium and occurs during the maximal movement of the heart within its pericardial sac. Thus, the rub can be heard during atrial systole, ventricular systole, and the rapid-filling phase of the ventricle (three-component rub). However, the rub may be present only during one (one component) or two phases (two components) of the cardiac cycle. In myopericarditis following transmural myocardial infarction, a one-component rub, usually during ventricular systole, is more frequent than two- or three-component rubs.",
"   </p>",
"   <p>",
"    Pericardial rubs are of scratching or grating quality and appear superficial. They are best heard with the diaphragm of the stethoscope. The intensity frequently increases after application of firm pressure with the diaphragm, during held inspiration, and with the patient leaning forward. The rub may be localized or widespread, but usually is heard over the left sternal border. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial rubs should be distinguished from the other superficial \"scratchy\" sounds.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with thyrotoxicosis, a to-and-fro, high-pitched sound may be heard over the left second interspace, known as a Means-Lerman scratch; it may simulate a pericardial friction rub. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute mediastinal emphysema, usually a benign, relatively common complication of open heart surgery, may be associated with a \"crunching\" noise over the precordium that is coincident with ventricular systole (mediastinal crunch).",
"     </li>",
"     <li>",
"      In patients with Ebstein's anomaly, the sail sound may be of a scratchy quality and simulate a pericardial friction rub.",
"     </li>",
"     <li>",
"      The movement of the balloon flotation catheter or the transvenous pacing catheter across the tricuspid valve can cause an early systolic superficial scratchy sound that may also simulate a soft, one-component friction rub. These sounds frequently disappear with the alteration of patient position.",
"     </li>",
"     <li>",
"      A pleuropericardial rub results from the friction between the inflamed pleura and the parietal pericardium; it can be heard only during the inspiratory phase of respiration.",
"     </li>",
"     <li>",
"      Twitching of the intercostal muscles or of the diaphragm during artificial pacing may cause a superficial scratchy and high-frequency sound unrelated to the cardiac cycle. This sound is called &ldquo;pacemaker heart sound&ldquo;. The twitching of the intercostal muscles results from stimulation of the adjacent intercostal nerves by the pacemaker stimulus [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadvertent entry of air into the right ventricular cavity via the systemic venous system may occur during placement of catheters or pacemakers in the right side of the heart or as a complication of needle aspiration biopsy of the lungs. The movement of air in the right ventricular cavity with systole and diastole may produce peculiar \"slushing\" or crunching sound (\"mill wheel\" murmur) over the entire precordium, which can occasionally resemble pericardial friction rub [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Swallowing sounds &mdash; These sounds are produced during swallowing and can be confused with heart sounds. It is postulated that these sounds are produced by vibrations of the vocal cords during swallowing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/56/22410/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27399972\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intensity of the first heart sound can be helpful in assessing left ventricular function and hemodynamics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A loud first heart sound in the absence of a short PR interval indicates increased peak rate of rise of left ventricular systolic pressure",
"      <span class=\"nowrap\">",
"       (dP/dt).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Increased intensity of S1'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      A soft first heart sound in the absence of prolonged PR interval usually indicates increased left ventricular end-diastolic pressure (LVEDP) and decreased peak",
"      <span class=\"nowrap\">",
"       dP/dt.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Decreased intensity of S1'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A paradoxical splitting of S2 in the absence of LBBB and in absence of left ventricular outflow obstruction indicates impaired contractile function. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Reversed (paradoxic) splitting of S2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An S3 gallop in adults in the absence of mitral regurgitation usually indicates elevated LVEDP and increased BNP levels. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Left ventricular gallops'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pericardial rub is characteristically a scratching or grating sound that may have one, two, or three components. (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Pericardial friction rub and other adventitious sounds'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/1\">",
"      LEATHAM A. Splitting of the first and second heart sounds. Lancet 1954; 267:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/2\">",
"      O'Toole JD, Reddy SP, Curtiss EI, et al. The contribution of tricuspid valve closure to the first heart sound. An intracardiac micromanometer study. Circulation 1976; 53:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/3\">",
"      Waider W, Craige E. First heart sound and ejection sounds. Echocardiographic and phonocardiographic correlation with valvular events. Am J Cardiol 1975; 35:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/4\">",
"      Laniado S, Yellin EL, Miller H, Frater RW. Temporal relation of the first heart sound to closure of the mitral valve. Circulation 1973; 47:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/5\">",
"      Luisada AA, MacCanon DM, Kumar S, Feigen LP. Changing views on the mechanism of the first and second heart sounds. Am Heart J 1974; 88:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/6\">",
"      Mills P, Craige E. Echophonocardiography. Prog Cardiovasc Dis 1978; 20:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/7\">",
"      Kostis JB. Letter: Mechanisms of heart sounds. Am Heart J 1975; 89:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/8\">",
"      Shah PM, Kramer DH, Gramiak R. Influence of the timing of atrial systole on mitral valve closure and on the first heart sound in man. Am J Cardiol 1970; 26:231.",
"     </a>",
"    </li>",
"    <li>",
"     Leatham A. Auscultation of the Heart and Phonocardiography, 2nd ed, J and A Churchill, London 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/10\">",
"      Dashkoff, N, Fortuin, NJ, Hutchins, GM. Clinical features of severe mitral regurgitation due to floppy mitral valve. Circulation 1974; 50(suppl 3):60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/11\">",
"      Mann T, McLaurin L, Grossman W, Craige E. Assessing the hemodynamic severity of acute aortic regurgitation due to infective endocarditis. N Engl J Med 1975; 293:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/12\">",
"      Crews TL, Pridie RB, Benham R, Leatham A. Auscultatory and phonocardiographic findings in Ebstein's anomaly. Correlation of first heart sound with ultrasonic records of tricuspid valve movement. Br Heart J 1972; 34:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/13\">",
"      Harris A. Pacemaker 'heart sound'. Br Heart J 1967; 29:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/14\">",
"      Sabbah HN, Stein PD. Investigation of the theory and mechanism of the origin of the second heart sound. Circ Res 1976; 39:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/15\">",
"      Hirschfeld S, Liebman J, Borkat G, Bormuth C. Intracardiac pressure-sound correlates of echographic aortic valve closure. Circulation 1977; 55:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/16\">",
"      Harris A, Sutton G. Second heart sound in normal subjects. Br Heart J 1968; 30:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/17\">",
"      Sutton G, Harris A, Leatham A. Second heart sound in pulmonary hypertension. Br Heart J 1968; 30:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/18\">",
"      LEATHAM A, GRAY I. Auscultatory and phonocardiographic signs of atrial septal defect. Br Heart J 1956; 18:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/19\">",
"      Leatham, A, Towers, M. Splitting of the second heart sound in health. Br Heart J 1951; 13:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/20\">",
"      Curtiss EI, Matthews RG, Shaver JA. Mechanism of normal splitting of the second heart sound. Circulation 1975; 51:157.",
"     </a>",
"    </li>",
"    <li>",
"     Shaver JA, O'Toole JD, Curtiss E, et al. Second heart sound. In: Physiological Principles of Heart Sounds and Murmurs, monograph No. 46, American Heart Association, New York 1975. p.58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/22\">",
"      BOYER SH, CHISHOLM AW. Physiologic splitting of the second heart sound. Circulation 1958; 18:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/23\">",
"      CASTLE RF, JONES KL. The mechanism of respiratory variation in splitting of the second heart sound. Circulation 1961; 24:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/24\">",
"      DORNHORST AC, HOWARD P, LEATHART GL. Respiratory variations in blood pressure. Circulation 1952; 6:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/25\">",
"      LEATHAM A, WEITZMAN D. Auscultatory and phonocardiographic signs of pulmonary stenosis. Br Heart J 1957; 19:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/26\">",
"      BRIGDEN W, LEATHAM A. Mitral incompetence. Br Heart J 1953; 15:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/27\">",
"      LEATHAM A, SEGAL B. Auscultatory and phonocar-diographic signs of ventricular septal defect with left to-right shunt. Circulation 1962; 25:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/28\">",
"      BECK W, SCHRIRE V, VOGELPOEL L. Splitting of the second heart sound in constrictive pericarditis, with observations on the mechanism of pulsus paradoxus. Am Heart J 1962; 64:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/29\">",
"      Damore, S, Murgo, JP, Bloom, KR, et al. Second heart sound dynamics in atrial septal defect. Circulation 1981; 64:IV28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/30\">",
"      GRAY IR. Paradoxical splitting of the second heart sound. Br Heart J 1956; 18:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/31\">",
"      YURCHAK PM, GORLIN R. PARADOXICAL SPLITTING OF THE SECOND HEART SOUND IN CORONARY HEART DISEASE. N Engl J Med 1963; 269:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/32\">",
"      Abrams J. Current concepts of the genesis of heart sounds. II. Third and fourth sounds. JAMA 1978; 239:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/33\">",
"      Ozawa Y, Smith D, Craige E. Origin of the third heart sound. II. Studies in human subjects. Circulation 1983; 67:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/34\">",
"      Ozawa, Y, Smith, D, Craige, E. Localization of the origin of the third heart sound. Circulation 1982; 66:II210.",
"     </a>",
"    </li>",
"    <li>",
"     Shah PM, Jackson D. Third heart sound and summation gallop. In: Physiologic Principles of Heart Sounds and Murmurs, monograph No. 46, Leon DF, Shaver JA (Eds), American Heart Association, New York 1975. p.79.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/36\">",
"      Abdulla AM, Frank MJ, Erdin RA Jr, Canedo MI. Clinical significance and hemodynamic correlates of the third heart sound gallop in aortic regurgitation. A guide to optimal timing of cardiac catheterization. Circulation 1981; 64:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/37\">",
"      Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/38\">",
"      Gerber, IL, McKeown, BH, Huddleson, M, et al. Echocardiographic, neurohormonal and invasively measured correlates of third and fourth heart sounds determined by audioelectric cardiography (abstract). J Am Soc Echocardiogr 2004; 17:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/39\">",
"      Marcus GM, Michaels AD, De Marco T, et al. Usefulness of the third heart sound in predicting an elevated level of B-type natriuretic peptide. Am J Cardiol 2004; 93:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/40\">",
"      Marcus GM, Gerber IL, McKeown BH, et al. Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA 2005; 293:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/41\">",
"      Ishmail AA, Wing S, Ferguson J, et al. Interobserver agreement by auscultation in the presence of a third heart sound in patients with congestive heart failure. Chest 1987; 91:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/42\">",
"      Lok CE, Morgan CD, Ranganathan N. The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation. Chest 1998; 114:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/43\">",
"      Drazner MH, Rame JE, Dries DL. Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular dysfunction. Am J Med 2003; 114:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/44\">",
"      Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/45\">",
"      Nixon, PG. The genesis of the third heart sound. Am Heart J 1963; 65:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/46\">",
"      Gibson TC, Madry R, Grossman W, et al. The A wave of the apexcardiogram and left ventricular diastolic stiffness. Circulation 1974; 49:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/47\">",
"      GOLDBLATT A, AYGEN MM, BRAUNWALD E. Hemodynamic-phonocardiographic correlations of the fourth heart sound in aortic stenosis. Circulation 1962; 26:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/48\">",
"      Hill JC, O'Rourke RA, Lewis RP, Mcgranahan GM. The diagnostic value of the atrial gallop in acute myocardial infarction. Am Heart J 1969; 78:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/49\">",
"      Sutton GC, Chatterjee K, Caves PK. Diagnosis of severe mitral regurgitation due to non-rheumatic chordal abnormalities. Br Heart J 1973; 35:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/50\">",
"      Kesteloot H, Willems J. Relationship between the right apex cardiogram and the right ventricular dynamics. Acta Cardiol 1967; 22:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/51\">",
"      Dayem MK, Wasfi FM, Bentall HH, et al. Investigation and treatment of constrictive pericarditis. Thorax 1967; 22:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/52\">",
"      Hancock, EW. The ejection sound in aortic stenosis. Am J Med 1966; 40:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/53\">",
"      Leech G, Mills P, Leatham A. The diagnosis of a non-stenotic bicuspid aortic valve. Br Heart J 1978; 40:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/54\">",
"      LEATHAM A, VOGELPOEL L. The early systolic sound in dilatation of the pulmonary artery. Br Heart J 1954; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/55\">",
"      Hultgren HN, Reeve R, Cohn K, McLeod R. The ejection click of valvular pulmonic stenosis. Circulation 1969; 40:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/56\">",
"      Curtiss EI, Reddy PS, O'Toole JD, Shaver JA. Alterations of right ventricular systolic time intervals by chronic pressure and volume overloading. Circulation 1976; 53:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/57\">",
"      Mills P, Amara I, McLaurin LP, Craige E. Noninvasive assessment of pulmonary hypertension from right ventricular isovolumic contraction time. Am J Cardiol 1980; 46:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/58\">",
"      Barlow JB, Bosman CK. Aneurysmal protrusion of the posterior leaflet of the mitral valve. An auscultatory-electrocardiographic syndrome. Am Heart J 1966; 71:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/59\">",
"      RONAN JA, PERLOFF JK, HARVEY WP. SYSTOLIC CLICKS AND THE LATE SYSTOLIC MURMUR; INTRACARDIAC PHONOCARDIOGRAPHIC EVIDENCE OF THEIR MITRAL VALVE ORIGIN. Am Heart J 1965; 70:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/60\">",
"      Leon DF, Leonard JJ, Kroetz FW, et al. Late systolic murmurs, clicks, and whoops arising from the mitral valve. A transseptal intracardiac phonocardiographic analysis. Am Heart J 1966; 72:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/61\">",
"      Criley JM, Lewis KB, Humphries JO, Ross RS. Prolapse of the mitral valve: clinical and cine-angiocardiographic findings. Br Heart J 1966; 28:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/62\">",
"      Mathey DG, Decoodt PR, Allen HN, Swan HJ. The determinants of onset of mitral valve prolapse in the systolic click-late systolic murmur syndrome. Circulation 1976; 53:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/63\">",
"      Behar VS, Whalen RE, McIntosh HD. The ballooning mitral valve in patients with the \"precordial honk\" or \"whoop\". Am J Cardiol 1967; 20:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/64\">",
"      Rackley CE, Whalen RE, Floyd WL, et al. The precordial honk. Am J Cardiol 1966; 17:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/65\">",
"      Sze KC, Shah PM. Pseudoejection sound in hypertrophic subaortic stenosis: an echocardiographic correlative study. Circulation 1976; 54:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/66\">",
"      Millward DK, McLaurin LP, Craige E. Echocardiographic studies to explain opening snaps in presence of nonstenotic mitral valves. Am J Cardiol 1973; 31:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/67\">",
"      Craige E. On the genesis of heart sounds. Contributions made by echocardiographic studies. Circulation 1976; 53:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/68\">",
"      Kalaria VG, Schwarz KQ, Eichelberger JP, Allen M. \"Vegetation plop\"--auscultatory findings in large mitral valve vegetation. Clin Cardiol 2000; 23:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/69\">",
"      Wei JY, Fortuin NJ. Diastolic sounds and murmurs associated with mitral valve prolapse. Circulation 1981; 63:559.",
"     </a>",
"    </li>",
"    <li>",
"     Spodick DH. Hypertrophic obstructive cardiomyopathy of the left ventricular (idiopathic hypertrophic subaortic stenosis). In: Cardiovascular Clinics, Burch GE, Brest AN (Eds), FA Davis, Philadelphia 1972. Vol 4, p.156.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/71\">",
"      Dayem MK, Raftery EB. Phonocardiogram of the ball-and-cage aortic valve prosthesis. Br Heart J 1967; 29:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/72\">",
"      Leachman RD, Cokkinos DV. Absence of opening click in dehiscence of mitral-valve prosthesis. N Engl J Med 1969; 281:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/73\">",
"      Assanelli D, Aquilina M, Marangoni S, et al. Echo-phonocardiographic evaluation of the Bj&ouml;rk-Shiley mitral prosthesis. Am J Cardiol 1986; 57:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/74\">",
"      Gottlieb JD, Ericsson JA, Sweet RB. Venous air embolism: a review. Anesth Analg 1965; 44:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/56/22410/abstract/75\">",
"      Cichero JA, Murdoch BE. The physiologic cause of swallowing sounds: answers from heart sounds and vocal tract acoustics. Dysphagia 1998; 13:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1079 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22410=[""].join("\n");
var outline_f21_56_22410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27399972\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STETHOSCOPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FIRST HEART SOUND (S1)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Increased intensity of S1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decreased intensity of S1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Variation in the intensity of S1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Splitting of S1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hemodynamic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pseudo splitting of S1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Reversed splitting of S1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SECOND HEART SOUND (S2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intensity of A2 and P2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Increased intensity of A2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Increased intensity of P2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Decreased intensity of A2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Decreased intensity of P2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Splitting of S2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Wide splitting of S2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Wide and \"fixed\" splitting of S2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Reversed (paradoxic) splitting of S2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Single S2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      THIRD (S3) AND FOURTH (S4) HEART SOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Auscultation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - General issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Distinguishing from split S2 or S1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Gallops",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Left ventricular gallops",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Right ventricular gallops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PERICARDIAL KNOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      EJECTION SOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Aortic ejection sound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Pulmonary ejection sound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      NON-EJECTION SYSTOLIC SOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Midsystolic click",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Precordial honk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Pseudo-ejection sound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      EARLY DIASTOLIC HIGH-FREQUENCY SOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Opening snap",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Mitral valve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Tumor plop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7936863\">",
"      Vegetation plop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      ARTIFICIAL VALVE SOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Ball variance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Valve malfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      PERICARDIAL FRICTION RUB AND OTHER ADVENTITIOUS SOUNDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27399972\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/58/4007\" title=\"figure 1\">",
"      Split S2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1079|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/55/8051\" title=\"movie 1\">",
"      Mitral valve prolapse with patient standing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/40/16004\" title=\"movie 2\">",
"      Mitral valve prolapse with patient squatting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/25/7571\" title=\"movie 3\">",
"      Mitral stenosis as heard at the apex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1079|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/6/35948\" title=\"table 1\">",
"      Causes S1 abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/33/14877\" title=\"table 2\">",
"      Causes S2 abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/16/13579\" title=\"table 3\">",
"      Causes early diastolic sounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/14/31980\" title=\"table 4\">",
"      Normal ausculatory findings of prosthetic valves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=related_link\">",
"      Management of patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_56_22411="Drugs associated with DRESS";
var content_f21_56_22411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with drug reaction with eosinophilia and systemic symptoms (DRESS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Frequently reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Also reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenindione",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluindione",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betalactam antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevirapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strontium ranelate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telaprevir",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22411=[""].join("\n");
var outline_f21_56_22411=null;
var title_f21_56_22412="Treatment syphilis in pregnancy";
var content_f21_56_22412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of syphilis in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage of syphilis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary/secondary/early latent",
"       </td>",
"       <td>",
"        Benzathine penicillin G*, 2.4 million units IM in a single dose (usually administered as 1.2 million units in each buttock)&bull;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Late latent/tertiary/unknown duration",
"       </td>",
"       <td>",
"        Benzathine penicillin G*, 7.2 million units total, administered as three doses of 2.4 million units IM each, at one week intervals",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Neurosyphilis&Delta;",
"       </td>",
"       <td>",
"        Aqueous crystalline penicillin G, 18 to 24 million units per day, administered as 3 to 4 million units IV every four hours or as a continuous infusion for 10 to 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procaine penicillin G, 2.4 million units IM once daily PLUS probenecid 500 mg PO four times daily, both for 10 to 14 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Pregnant women are treated with the penicillin regimen appropriate for their stage of infection. Parenteral penicillin G is the only therapy with documented efficacy during pregnancy. If penicillin allergy, skin test and desensitize as necessary. Some evidence suggests that additional therapy can be beneficial for pregnant women in some settings (eg, a second dose of benzathine penicillin 2.4 million units IM administered one week after the initial dose for women who have primary, secondary, or early latent syphilis). (Wendel GD Jr, Sheffield JS, Hollier LM, et al. Treatment of syphilis in pregnancy and prevention of congenital syphilis. Clin Infect Dis 2002; 35(Suppl 2):S200).",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous; PO: oral.",
"     <br>",
"      * US trade name Bicillin&reg; L-A for benzathine penicillin G (benzathine benzylpenicillin) suspension for deep IM injection only. Verify product to prevent confusion with other penicillin preparations.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       If serologic failure at follow up and additional follow up cannot be assured, can re-treat with Benzathine penicillin G 2.4 million units IM for three weeks. Prompt CSF examination recommended.",
"       <br>",
"        &Delta; Benzathine penicillin G 2.4 million units IM once per week for up to three weeks may be administered after completion of neurosyphilis regimen to complete a three week course.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010 available at:",
"     <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm?s_cid=rr5912a1_w\" target=\"_blank\">",
"      file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm?s_cid=rr5912a1_w",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22412=[""].join("\n");
var outline_f21_56_22412=null;
var title_f21_56_22413="Cryofibrinogen associations";
var content_f21_56_22413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with cryofibrinogenemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Essential (idiopathic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Connective tissue and autoimmune diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giant cell arteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hashimoto's thyroiditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IgA nephropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory muscle disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polyarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psoriasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial Mediterranean fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Graves' disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Henoch-Schonlein purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary billiary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sjogren's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlamydia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis C",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trypanosomiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Varicella-Zoster virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colitis, infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Post-respiratory infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptococcus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignancies and neoplastic conditions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gallbladder cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myelodysplastic syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prostate cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial myxoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Head and neck cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myeloproliferative disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ovarian cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drug related: Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Severe athersclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Homocystinuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Factor XII deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22413=[""].join("\n");
var outline_f21_56_22413=null;
var title_f21_56_22414="Cetuximab vinorelbine and cisplatin chemotherapy for NSCLC";
var content_f21_56_22414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cetuximab, vinorelbine, and cisplatin chemotherapy for advanced non-small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days for a maximum of six cycles; this is followed by maintenance cetuximab.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cetuximab",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes (maximum 10 mg/min)*",
"        <sup>",
"         &Delta;",
"        </sup>",
"        . Cetuximab is given prior to chemotherapy agents on days when both are administered.",
"       </td>",
"       <td>",
"        Day 1, first cycle only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cetuximab",
"        </strong>",
"       </td>",
"       <td>",
"        250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        If Day 1 dose is tolerated, subsequent doses may be administered over 60 minutes",
"        <sup>",
"         &Delta;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Weekly, beginning on day 8 of first cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vinorelbine",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in normal saline (NS) to a final concentration between 0.5 and 2 mg/mL and administer over 6 to 10 minutes into the side port of a free-flowing IV infusion.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over two hours. Do not administer with aluminum needles or intravenous sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH on day 1 of each cycle (cisplatin); LOW when cetuximab plus vinorelbine or cetuximab alone are given. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedication with diphenhydramine with or without a glucocorticoid at least prior to the first infusion of cetuximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Vinorelbine is a vesicant and can cause significant tissue damage. Cisplatin is an irritant. Avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The incidence of febrile neutropenia with this regimen is 16 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        . The decision whether or not to use hematopoietic growth factors must be individualized. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . A lower starting dose of vinorelbine may be needed for patients with hepatic impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Basic metabolic panel (creatinine and electrolytes, including magnesium, calcium, and potassium) prior to each treatment dose. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy",
"        <sup>",
"         [2]",
"        </sup>",
"        . Replete electrolytes as necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assay for liver function prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess for skin rash.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Treatment on day 1 of each cycle with cisplatin and vinorelbine should be delayed for up to two weeks until ANC is &gt;1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        , platelet count &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , and hemoglobin &gt;9.0 g/dL",
"        <sup>",
"         [3]",
"        </sup>",
"        . If longer delays are required, treatment with these agents should be discontinued. Day 8 vinorelbine should be omitted if ANC &lt;1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &lt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Doses of vinorelbine and cisplatin should be reduced to 20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        and 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , respectively, for patients who have had neutropenic fever in a prior cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dermatologic toxicity:",
"        </strong>",
"        Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. Refer to UpToDate topic on \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        The FDA-approved package insert recommends dose reduction for patients who develop hyperbilirubinemia during treatment with vinorelbine. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.",
"     <br/>",
"     * A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the Southeast United States). Refer to UpToDate topic on \"Infusion reactions to the therapeutic monoclonal antibodies used in cancer therapy\".",
"     <br/>",
"     &Delta; Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line fitter. Do not shake or dilute. Flush line with normal saline.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pirker R, et al. Lancet 2009; 373:1525.",
"      </li>",
"      <li>",
"       Erbitux (cetuximab) for injection. FDA-approved product information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 7, 2009).",
"      </li>",
"      <li>",
"       Rosell R, et al. Ann Oncol 2008; 19:362.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22414=[""].join("\n");
var outline_f21_56_22414=null;
var title_f21_56_22415="Impaired TM mobility";
var content_f21_56_22415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/67928/pneumat2_conv.mp4?title=Impaired+TM+mobility\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tympanic membrane with impaired mobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A maximally retracted tympanic membrane may be unable to move away from the observer with positive pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen R Wald, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_56_22415=[""].join("\n");
var outline_f21_56_22415=null;
